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A B S T R A C T
Background
Gastric cancer is the third most common cause of cancer-related mortality in the world. Currently there are two surgical options for
potentially curable patients (i.e. people with non-metastatic gastric cancer), laparoscopic and open gastrectomy. However, it is not clear
whether one of these options is superior.
Objectives
To assess the benefits and harms of laparoscopic gastrectomy or laparoscopy-assisted gastrectomy versus open gastrectomy for people
with gastric cancer. In particular, we planned to investigate the effects by patient groups, such as cancer stage, anaesthetic risk, and
body mass index (BMI), and by intervention methods, such as method of anastomosis, type of gastrectomy and laparoscopic or
laparoscopically-assisted gastrectomy.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Science Citation Index, Clin-
icalTrials.gov and the WHO ICTRP (World Health Organization International Clinical Trials Registry Platform) until September
2015. We also screened reference lists from included trials.
Selection criteria
Two review authors independently selected references for further assessment by going through all titles and abstracts. Further selection
was based on review of full text articles for selected references.
Data collection and analysis
Two review authors independently extracted study data. We calculated the risk ratio (RR) with 95% confidence interval (CI) for binary
outcomes, the mean difference (MD) or the standardised mean difference (SMD) with 95% CI for continuous outcomes and the
hazard ratio (HR) for time-to-event outcomes. We performed meta-analyses where it was meaningful.
Main results
In total, 2794 participants were randomised in 13 trials included in this review. All the trials were at unclear or high risk of bias. One
trial (which included 53 participants) did not contribute any data to this review. A total of 213 participants were excluded in the
remaining trials after randomisation, leaving a total of 2528 randomised participants for analysis, with 1288 undergoing laparoscopic
gastrectomy and 1240 undergoing open gastrectomy. All the participants were suitable for major surgery.
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There was no difference in the proportion of participants who died within thirty days of treatment between laparoscopic gastrectomy
(7/1188: adjusted proportion = 0.6% (based on meta-analysis)) and open gastrectomy (4/1447: 0.3%) (RR 1.60, 95% CI 0.50 to
5.10; risk difference 0.00, 95% CI -0.01 to 0.01; participants = 2335; studies = 11; I2 = 0%; low quality evidence). There were no
events in either group for short-term recurrence (participants = 103; studies = 3), proportion requiring blood transfusion (participants
= 66; studies = 2), and proportion with positive margins at histopathology (participants = 28; studies = 1). None of the trials reported
health-related quality of life, time to return to normal activity or time to return to work. The differences in long-term mortality (HR
0.94, 95% CI 0.70 to 1.25; participants = 195; studies = 3; I2 = 0%; very low quality evidence), serious adverse events within three
months (laparoscopic gastrectomy (7/216: adjusted proportion = 3.6%) versus open gastrectomy (13/216: 6%) (RR 0.60, 95% CI
0.27 to 1.34; participants = 432; studies = 8; I2 = 0%; very low quality evidence), long-term recurrence (HR 0.95, 95% CI 0.70 to
1.30; participants = 162; studies = 4; very low quality evidence), adverse events within three months (laparoscopic gastrectomy (204/
268: adjusted proportion = 16.1%) versus open gastrectomy (253/1222: 20.7%) (RR 0.78, 95% CI 0.60 to 1.01; participants = 2490;
studies = 11; I2 = 38%; very low quality evidence), quantity of perioperative blood transfused (SMD 0.05, 95% CI -0.27 to 0.38;
participants = 143; studies = 2; I2 = 0%; very low quality evidence), length of hospital stay (MD -1.82 days, 95% CI -3.72 to 0.07;
participants = 319; studies = 6; I2 = 83%; very low quality evidence), and number of lymph nodes harvested (MD -0.63, 95% CI -
1.51 to 0.25; participants = 472; studies = 9; I2 = 40%; very low quality evidence) were imprecise. There was no alteration in the
interpretation of the results in any of the subgroups.
Authors’ conclusions
Based on low quality evidence, there is no difference in short-term mortality between laparoscopic and open gastrectomy. Based on
very low quality evidence, there is no evidence for any differences in short-term or long-term outcomes between laparoscopic and
open gastrectomy. However, the data are sparse, and the confidence intervals were wide, suggesting that significant benefits or harms
of laparoscopic gastrectomy cannot be ruled out. Several trials are currently being conducted and interim results of these trials have
been included in this review. These trials need to perform intention-to-treat analysis to ensure that the results are reliable and report
the results according to the CONSORT Statement.
P L A I N L A N G U A G E S U M M A R Y
Laparoscopic (key hole) operation versus open operation for treatment of people with stomach cancer
Review question
Is laparoscopic treatment (key hole surgery) equivalent to open surgical treatment for treatment of people with gastric (stomach) cancer?
Background
Stomach cancer is the third most frequent cause of cancer-related death in the world. If cancer has not spread to other areas of the
body, and if the person can withstand a major operation, depending upon the part of the stomach involved, removal of part of the
stomach, or the entire stomach (gastrectomy), is the only treatment that offers long-term cure of cancer. Gastrectomy can be performed
by laparoscopic (key hole) operation, or by open operation, which involves a large cut. While the cut is smaller with key hole surgery,
it is not clear whether key hole surgery is as safe as open surgery, and whether it offers any advantages in terms of quicker recovery of
people undergoing gastrectomy. We sought to resolve this issue by searching the medical literature for studies reported until September
2015 that compared laparoscopic and open gastrectomy in people with stomach cancer.
Study characteristics
We identified 13 eligible studies (2794 participants) for this review.One trial did not report any information that we sought. Information
on 213 participants was not reported because of various reasons, the common reason being that they did not receive the planned
treatment. A total of 2528 participants received either laparoscopic gastrectomy (1288 participants) or open gastrectomy (1240
participants). The decision on whether a participant received laparoscopic or open gastrectomy was made using methods similar to
the toss of a coin. This process ensures that the participants in the two groups are similar. All the participants were suitable for major
surgery.
Key results
There was no difference between laparoscopic and open gastrectomy in short-term deaths (laparoscopic gastrectomy: 6 deaths in 1000
operations versus open gastrectomy: 3 deaths in 1000 operations). There is a certain amount of uncertainty when predicting the number
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of deaths or outcomes based on information in the trials. Because of this uncertainty, we were able to conclude that there was no
difference in short-term deaths between the groups, although the deaths in laparoscopic gastrectomy was twice that in open gastrectomy.
None of the trials reported health-related quality of life, time to return to normal activity or time to return to work. The differences
in long-term deaths, serious complications within three months (laparoscopic gastrectomy: 36 complications per 1000 operations
versus open gastrectomy: 60 complications per 1000 operations), all complications within three months (laparoscopic gastrectomy:
161 complications per 1000 operations versus open gastrectomy: 253 complications in 1000 operations, short-term and long-term
recurrence of cancer, number of people who required blood transfusion, amount of blood transfused during or within one week of
surgery, and length of hospital stay were imprecise. As a result, significant benefits or harms of laparoscopic gastrectomy compared to
open gastrectomy cannot be ruled out. Further well designed trials are necessary to compare the benefits and harms of laparoscopic and
open gastrectomy.
Quality of the evidence
The quality of evidence was very low for all outcomes, apart from short-term mortality, which was low. As a result, there is a lot of
uncertainty regarding the results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Laparoscopic gastrectomy compared to open gastrectomy for gastric cancer (primary outcomes)
Patient or population: patients with gastric cancer
Settings: secondary or tertiary setting
Intervention: laparoscopic gastrectomy
Comparison: open gastrectomy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Open gastrectomy Laparoscopic gastrectomy
Short-term mortality 3 per 1000 6 per 1000
(2 to 18)
RR 1.60
(0.50 to 5.10)
2335
(11 studies)
⊕⊕©©
low1
Long-term mortality (maxi-
mal follow-up)
448 per 1000 428 per 1000
(340 to 524)
HR 0.94
(0.70 to 1.25)
195
(3 studies)
⊕©©©
very low1,2
Proportion with a serious ad-
verse event (<3 months)
60 per 1000 36 per 1000
(16 to 81)
RR 0.60
(0.27 to 1.34)
432
(8 studies)
⊕©©©
very low1,2
Health-related quality of life during short-term (four weeks to three months) or medium-term (more than three months to one year) was not reported
*The basis for the assumed risk was the mean control group proportion. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; HR: hazard ratio; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 There was unclear or high risk bias within the trials (downgraded by two levels).4
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2 The confidence intervals were wide (overlaps no effect and clinically significantly effect) and the sample size was small (downgraded
by two levels).
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B A C K G R O U N D
Description of the condition
Adenocarcinoma of the stomach (or stomach cancer) is the fifth
most common cancer and the third most common cause of can-
cer-related mortality in the world (IARC 2014). In 2012, there
were about 950,000 newly diagnosed cases of gastric cancer and
725,000 deaths due to gastric cancer globally (IARC 2014). There
is global variation in the incidence of gastric cancers with an age-
standardised annual incidence rate of 30 to 42 per 100,000 popu-
lation in East Asian countries such as Japan, Mongolia, and Korea
compared with an age-standardised annual incidence rate of 1 to 5
per 100,000 population in Africa, Australia, the USA, and the UK
(IARC 2014). The trend in mortality is different. For example,
the age-standardised annual mortality rate in Mongolia is 25 per
100,000 population compared with 13 per 100,000 population
in Korea and Japan despite a higher age-standardised annual inci-
dence in Korea than Mongolia (IARC 2014).
There is a decreasing trend in the overall incidence of gastric can-
cers, possibly due to lifestyle changes, such as decreased consump-
tion of salted and preserved foods, increased consumption of fruits
and vegetables, decreased smoking and reduction ofHelicobacter
pylori (H. pylori) (Cancer Research UK 2014; Jemal 2010).
The treatment of gastric cancer depends upon the stage of cancer.
One of the common systems for staging cancer currently is the
American Joint Committee on Cancer (AJCC) gastric cancer stag-
ing system - AJCC 7th edition (AJCC 2010; Washington 2010).
This system is based on the involvement of the different layers
of the stomach by the tumour (T), nodal involvement (N), and
the presence of metastases (M) (TNM classification). Early gastric
cancer is cancer that is confined to the submucosa (T1) with or
without nodal involvement, although this definition of early gas-
tric cancer has been challenged since nodal status is an important
prognostic factor in survival (Inoue 1991; Kim1995). If the cancer
has penetrated beyond the submucosa, it is called advanced gastric
cancer. Metastatic gastric cancer corresponds to Stage IV of the
AJCC gastric cancer staging system. The survival after diagnosis of
gastric cancer depends upon the stage with five-year survival rang-
ing from 70% in Stage Ia cancer to 5% in Stage IV cancer (AJCC
2010;Washington 2010). The treatment of gastric cancer depends
upon the stage of the disease. Potentially curative treatment is
possible for stages I to III (Japanese Gastric Cancer Association
2011; Waddell 2013). Apart from T1aN0M0 stage, where endo-
scopic treatment may be performed, and stage IV, where palliative
treatment is recommended, the remaining stages are treated by
resection of the stomach (gastrectomy) (Bennett 2009; Japanese
Gastric Cancer Association 2011; Waddell 2013).
Description of the intervention
In open gastrectomy, the surgical access to the abdominal cavity
(and hence the stomach) is by upper midline incision, a bilateral
subcostal incision (roof-top or Chevron incision), or a transverse
abdominal incision (Inaba 2004; Stuart 1997). In laparoscopy-
assisted gastrectomy, the surgical access to the abdominal cavity
(and hence the stomach) is by a small abdominal incision (about
5 cm) and additional five or six small ports (holes) of about 0.5
cm to 1 cm each through which laparoscopic instruments can
be inserted after the abdomen is distended using carbon dioxide
pneumoperitoneum. Part of the surgery, usually the anastomosis
restoring the continuity of the gastrointestinal tract, is performed
outside the body (extracorporeal) (Lee 2013). The resected stom-
ach is removed through the small abdominal incision. In totally
laparoscopic gastrectomy, the surgical access to the abdominal cav-
ity (and hence the stomach) is only by five or six small ports of
about 0.5 to 1 cm each through which laparoscopic instruments
can be inserted after the abdomen is distended using carbon diox-
ide pneumoperitoneum. The entire surgery is performed laparo-
scopically (Zhang 2015).
The standard operations are total gastrectomy and subtotal gastrec-
tomy, and are recommended in the presence of nodal involvement
or T2 to T4a tumours. Subtotal gastrectomy can be performed
when a minimum of 2 to 5 cm proximal cancer-free margin can
be achieved, depending upon the depth of infiltration and the
growth pattern of the cancer (Japanese Gastric Cancer Association
2011). Proximal gastrectomy can be performed for T1N0 proxi-
mal gastric cancers when more than half of the distal stomach can
be preserved; and a pylorus-preserving gastrectomy can be per-
formed for T1N0 cancers of the middle third of the stomach when
the distal margin of the tumour is at least 4 cm from the pylorus
(Japanese Gastric Cancer Association 2011). The extent of lymph
node excision, and the method of restoration of continuity of the
gastrointestinal tract, are controversial (Japanese Gastric Cancer
Association 2011; Memon 2011; Waddell 2013; Xiong 2013).
Postoperative chemotherapy is recommended after gastrectomy
for resectable gastric cancer (Diaz-Nieto 2013; Waddell 2013).
How the intervention might work
For many surgical procedures, laparoscopic surgery is currently
preferred over open surgery. This includes surgical procedures such
as cholecystectomy (removal of gallbladder), colon cancer, and
hysterectomy (Bijen 2009; Keus 2006; Reza 2006; Talseth 2014;
Walsh 2009). The reason for this preference of laparoscopic surgery
over open surgery is because of decreased pain, decreased blood
loss, shorter hospital stay, earlier postoperative recovery, better
cosmesis (physical appearance), and decreased costs (Bijen 2009;
Keus 2006; Reza 2006; Talseth 2014; Walsh 2009).
Why it is important to do this review
6Laparoscopic versus open gastrectomy for gastric cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
While the smaller incision and earlier postoperative recovery ap-
pear to be potential advantages of laparoscopic gastrectomy or la-
paroscopy-assisted gastrectomy, the safety of the laparoscopic ap-
proach (for a procedure that has a high complication rate) and
cancer clearance after laparoscopic and laparoscopy-assisted gas-
trectomy has to be ensured before the method can be widely rec-
ommended. There are concerns about cancer clearance, since port
site metastases (recurrence of cancer at the laparoscopic port site)
have been reported after many cancers (Kais 2014; Palomba 2014;
Song 2014). Animal research has shown that the increased in-
tra-abdominal pressure during laparoscopy (pneumoperitoneum)
may drive themalignant cells into ports, resulting in seeding of the
port site and port site metastases (Hopkins 1999). Another reason
is that the malignant cells may be adherent to the laparoscopic in-
struments that are introduced and removed through the ports, re-
sulting in seeding of the port site and port sitemetastases (Hopkins
1999). Another issue is the adequacy of cancer clearance in terms
of resection margins and the extent of lymph nodes removed with
laparoscopy. Therefore, oncological safety (cancer clearance) is an
important issue with laparoscopic and laparoscopic-assisted gas-
trectomy. There is no Cochrane review on this topic.
O B J E C T I V E S
To assess the benefits and harms of laparoscopic gastrectomy or
laparoscopy-assisted gastrectomy versus open gastrectomy for peo-
ple with gastric cancer. In particular, we planned to investigate the
effects by patient groups, such as cancer stage, anaesthetic risk,
and body mass index (BMI), and by intervention methods, such
as method of anastomosis, type of gastrectomy and laparoscopic
or laparoscopically-assisted gastrectomy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs). We included
studies reported as full text, studies published as abstract only, and
unpublished data.
Types of participants
We included adults undergoing gastrectomy for gastric adenocar-
cinoma (cancer). We included trials in which separate outcome
data for people undergoing gastrectomy for gastric adenocarci-
noma were available, even if some of the participants underwent
gastrectomy for other causes, including lymphomas.
Types of interventions
We included trials comparing laparoscopic gastrectomy or la-
paroscopy-assisted gastrectomy with open gastrectomy, provided
that the only difference between the randomised groups was the
use of laparoscopic (or laparoscopy-assisted) or open method of
access to the stomach. We excluded trials comparing totally la-
paroscopic gastrectomy with laparoscopy-assisted gastrectomy or
different methods of open or laparoscopic gastrectomy. We also
excluded any trials comparing robot-assisted gastrectomy with la-
paroscopic or open gastrectomy.
Types of outcome measures
Primary outcomes
1. Mortality
i) Short-term mortality (in-hospital mortality or
mortality within three months)
ii) Long-term mortality (at maximal follow-up)
2. Serious adverse events (within three months). We accepted
the following definitions of serious adverse events.
i) Clavien-Dindo classification (Clavien 2009; Dindo
2004): Grade III or more.
ii) International Conference on Harmonisation - Good
Clinical Practice guideline (ICH-GCP; ICH-GCP 1996):
serious adverse events defined as any untoward medical
occurrence that results in death, is life-threatening, requires
hospitalisation or prolongation of existing hospitalisation, and
results in persistent or significant disability/incapacity.
iii) Individual complications that could clearly be
classified as Grade III or more with the Clavien-Dindo
classification (Clavien 2009; Dindo 2004), or as a serious adverse
event with the ICH-GCP classification.
3. Health-related quality of life (using any validated scale)
i) Short-term (four weeks to three months)
ii) Medium-term (more than three months to one year)
Secondary outcomes
1. Recurrence (local recurrence, surgical wound recurrence
(also called port site metastases in the laparoscopic group) or
distal metastases)
i) Short-term recurrence (within six months)
ii) Long-term recurrence (at maximal follow-up)
2. Adverse events (within three months). We accepted all
adverse events reported by the study author irrespective of the
severity of the adverse event.
3. Perioperative blood transfusion requirements (during
surgery or within one week after surgery) (whole blood or red
cell transfusion).
i) Proportion of people requiring blood transfusion
ii) Quantity of blood transfusion
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4. Measures of earlier postoperative recovery
i) Length of hospital stay (including the index admission
for gastrectomy and any surgical complication-related re-
admission)
ii) Time to return to normal activity (return to
preoperative mobility without any additional carer support)
iii) Time to return to work (in people who were employed
previously)
5. Positive resection margins (presence of macroscopic or
microscopic cancer tissue at the plane of resection) at
histopathological examination after surgery.
6. Number of lymph nodes harvested during surgery.
We based the choice of the above clinical outcomes on the neces-
sity to assess whether laparoscopic surgery results in adequate can-
cer clearance, is safe, and is beneficial in terms of decreased blood
transfusion requirements; earlier postoperative recovery allowing
earlier discharge from hospital, return to normal activity, and re-
turn to work; and improvement in health-related quality of life.
We highlight that the positive resection margins at histopatho-
logical examination after surgery, and the number of harvested
lymph nodes during surgery, are surrogate outcomes, and we have
included these in order to explore whether these are responsible
for any differences in survival or mortality.
We included studies which met the inclusion criteria, irrespective
of whether they reported the secondary outcomes.
Search methods for identification of studies
Electronic searches
We conducted a literature search to identify all published and un-
published RCTs. The literature search identified potential studies
in all languages. We translated the non-English language papers
and assessed them fully for potential inclusion in the review as
necessary.
We searched the following electronic databases for identifying po-
tential studies.
1. The Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 9) (Appendix 1).
2. MEDLINE (1966 to September 2015) (Appendix 2).
3. EMBASE (1988 to September 2015) (Appendix 3).
4. Science Citation Index (1982 to September 2015)
(Appendix 4).
We also conducted a search of
ClinicalTrials.gov (ClinicalTrials.gov; Appendix 5) and the World
Health Organization - International Clinical Trials Registry Plat-
form (WHO ICTRP; www.who.int/ictrp/en/; Appendix 6). We
performed all the searches on 5 September 2015.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references. We contacted authors of identified
trials and asked them to identify other published and unpublished
studies.
We searched for errata or retractions fromeligible trials onPubMed
on 7 October 2015 (www.ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
Selection of studies
Two review authors (LB and KG) independently screened titles
and abstracts for inclusion all the potential studies that we identi-
fied as a result of the search and coded them as ’retrieve’ (eligible
or potentially eligible/unclear) or ’do not retrieve’ (ineligible). We
retrieved the full text study reports for coded as ’retrieve’ and two
review authors (LB and KG) independently screened the full text,
identified studies for inclusion, and identified and recorded rea-
sons for exclusion of the ineligible studies. We resolved any dis-
agreements through discussion. We identified and excluded dupli-
cates and collated multiple reports of the same study so that each
study, rather than each report, is the unit of interest in the review.
We recorded the selection process in sufficient detail to complete
a PRISMA flow diagram (Moher 2009), and Characteristics of
excluded studies table.
Data extraction and management
We used a standard data collection form for study characteristics
and outcome data that had been piloted on at least one study in the
review.Two review authors (LB andKG) extracted study character-
istics from included studies and detailed them in a Characteristics
of included studies table. We extracted the following study char-
acteristics.
1. Methods: study design, total duration of the study and run
in, number of study centres and location, study setting,
withdrawals, and date of study.
2. Participants: number, mean age, gender, tumour stage,
tumour location, American Society of Anesthesiologists (ASA)
status (ASA 2014), inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, and concomitant
interventions.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors (LB and KG) independently extracted out-
come data from included studies. If outcomeswere reportedmulti-
ple times for the same time frame (for example, short-term health-
related quality of life was reported at six weeks and three months),
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we chose the later time point (i.e. three months) for data extrac-
tion. For time-to-event outcomes where data is censored, we ex-
tracted data to calculate the natural logarithm of the hazard ra-
tio (HR) and its standard error using the methods suggested in
Parmar 1998.
We included all randomised participants for medium-term and
long-term outcomes (e.g. mortality or quality of life), and this was
not conditional upon the short-term outcomes (e.g. being alive at
three months or having a low or high quality of life index at three
months).
We noted in the Characteristics of included studies table if out-
come data are reported in an unusable way. We resolved disagree-
ments by consensus.One review author (LB) copied across the data
from the data collection form into Review Manager 5 (RevMan
2014). We double-checked that the data were entered correctly by
comparing the study reports with how the data are presented in
the systematic review.
Assessment of risk of bias in included studies
Two review authors (LB and KG) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion. We assessed the risk
of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear
risk of bias and provided a quotation from the study report to-
gether with a justification for our judgement in the ’Risk of bias’
table. We summarised the risk of bias judgements across differ-
ent studies for each of the domains listed. We considered blind-
ing separately for different key outcomes where necessary (e.g. for
unblinded outcome assessment, risk of bias for all-cause mortal-
ity may be very different from a participant-reported pain scale).
Where information on risk of bias related to unpublished data or
correspondence with a trial author, we noted this in the ’Risk of
bias’ table.
We considered trials were at low risk of bias in all domains to be
at overall low risk of bias. Other trials were considered to be at
unclear or high risk of bias. When considering treatment effects,
we took into account the risk of bias for the studies that contribute
to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol
and reported any deviations from it in the Differences between
protocol and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as risk ratios (RRs) with 95% CIs
and continuous data as mean differences (MDs) with 95% CIs
when the outcome was reported or converted to the same units
in all the trials (e.g. hospital stay, time to return to work) or stan-
dardised mean differences (SMDs) with 95% CIs when different
scales were used for measuring the outcome (e.g. quality of life).
We ensured that higher scores for continuous outcomes had the
same meaning for the particular outcome, explained the direction
to the reader, and reported where the directions were reversed, if
this was necessary. We calculated the rate ratio (RaR) with 95%
CIs for outcomes such as adverse events and serious adverse events,
where it is possible for the same person to develop more than one
adverse event (or serious adverse event). We did not identify any
studies that reported the RaR of adverse events (or serious adverse
events) in the intervention versus control based on Poisson regres-
sion. We calculated the HR for time-to-event outcomes such as
long-term mortality, long-term recurrence, and time-to-first ad-
verse event (or serious adverse event).
We undertook meta-analyses only where this was meaningful (i.e.
if the treatments, participants, and the underlying clinical question
were similar enough for pooling to make sense).
A common way that trial authors indicate when they have skewed
data is by reporting medians and interquartile ranges. When we
encountered this, we noted that the data were skewed by following
the rough guide for identifying skewed distribution available in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011), and considered the implication of this.
Where multiple trial arms were reported in a single trial, we
included only the relevant arms. If two comparisons (e.g. la-
paroscopy-assisted gastrectomy versus open gastrectomy and to-
tally laparoscopic gastrectomy versus open gastrectomy) had to be
entered into the same meta-analysis, we halved the control group
to avoid double-counting. The alternative way of including such
trialswithmultiple arms is to pool the results of the laparoscopy-as-
sisted gastrectomy and totally laparoscopic gastrectomy and com-
pare it with open gastrectomy. We performed a sensitivity analysis
to determine if the results of the two methods of dealing with
multi-arm trials led to different conclusions.
Unit of analysis issues
The unit of analysis was individual participants undergoing gas-
trectomy. We did not encounter any cluster-randomised trials for
this review, and therefore did not require any specificmethodology
for this trial type.
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Dealing with missing data
We contacted investigators or study sponsors in order to verify key
study characteristics and obtain missing numerical outcome data
where possible (e.g. when a study is identified as abstract only). If
we were unable to obtain the information from the investigators or
study sponsors, we imputed mean from median (i.e. consider me-
dian as the mean) and standard deviation from standard error, in-
terquartile range, or P values according to the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), but assessed
the impact of including such studies in a sensitivity analysis. If we
were unable to calculate the standard deviation from the standard
error, interquartile range, or P values, we imputed the standard
deviation as the highest standard deviation in the remaining trials
included in the outcome, fully aware that this method of imputa-
tion will decrease the weight of the studies in the meta-analysis of
MD and shift the effect towards no effect for SMD.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity as per
the Cochrane Handbook for Systematic Reviews of Interventions (i.e.
greater than 50% to 60%; Higgins 2011), we explored it by pre-
specified subgroup analysis.
Assessment of reporting biases
We attempted to contact study authors, asking them to provide
missing outcome data. Where this was not possible, and the miss-
ing data were thought to introduce serious bias, we explored the
impact of including such studies in the overall assessment of results
using a sensitivity analysis.
If we were able to pool more than 10 trials, we created and ex-
amined a funnel plot to explore possible publication biases. We
used Egger’s test to determine the statistical significance of the re-
porting bias (Egger 1997). We considered a P value less than 0.05
statistically significant for reporting bias.
Data synthesis
We performed analyses using Review Manager 5 (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Totally laparoscopic and laparoscopy-assisted gastrectomy.
2. Different cancer stages (early gastric cancer and advanced
gastric cancer; node-positive and node-negative gastric cancer).
For this, we defined early gastric cancer as tumours confined to
mucosa and submucosa, irrespective of lymph node metastasis
(Japanese Gastric Cancer Association 2011).
3. Different types of gastrectomy (proximal, pylorus-
preserving, subtotal, total gastrectomy).
4. Different methods of anastomoses (stapler versus hand-
sewn anastomoses).
5. People with different anaesthetic risk (ASA I (a healthy
person) or ASA II (a person with mild systemic disease) versus
ASA III or more (a person with severe systemic disease or worse).
6. Different body mass index (BMI) (healthy weight (BMI
18.5 to 25) versus overweight or obese (BMI 25 or greater).
We used all primary outcomes in subgroup analyses.
We used the formal Chi2 test for subgroup differences to test for
subgroup interactions.
Sensitivity analysis
We performed sensitivity analyses defined a priori, to assess the
robustness of our conclusions. These involved:
1. excluding trials at unclear or high risk of bias (one of more
of the risk of bias domains (other than blinding of surgeon)
classified as unclear or high);
2. excluding trials in which either mean or standard deviation,
or both are imputed;
3. excluding cluster-RCTs in which the adjusted effect
estimates are not reported; and
4. different methods of dealing with multi-arm trials (see
Measures of treatment effect).
’Summary of findings’ table
We created two ’Summary of findings’ tables. Summary of findings
for the main comparison includes all of the pre-specified primary
outcomes that have been reported in the studies (short-term mor-
tality, long-term mortality, and serious adverse events); Summary
of findings 2 includes all of the pre-specified secondary outcomes
that have been reported in the studies (long-term recurrence, ad-
verse events, perioperative blood transfused, length of hospital
stay, and number of lymph nodes harvested). We used the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness, and publication bias) to assess the qual-
ity of a body of evidence as it related to the studies that con-
tributed data to the meta-analyses for the pre-specified outcomes.
We used methods and recommendations described in Section 8.5
and Chapter 12 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), and using GRADEproGDT soft-
ware (GRADEproGDT 2015).We justified all decisions to down-
grade or upgrade the quality of studies using footnotes and made
comments to aid reader’s understanding of the review, where nec-
essary. We considered whether there was any additional outcome
information that we were unable to incorporate into the meta-
analyses, noted this in the comments, and stated if it supported or
contradicted the information from the meta-analyses.
Reaching conclusions
Webased our conclusions only onfindings from the quantitative or
narrative synthesis of included studies for this review. We avoided
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making recommendations for practice, and our Implications for
research will give the reader a clear sense of where the focus of
any future research in the area should be, and what the remaining
uncertainties are.
R E S U L T S
Description of studies
Results of the search
We identified 18,369 references through electronic searches of
the Cochrane Central Register of Controled trials (CENTRAL),
MEDLINE, EMBASE, Science Citation Index, ClinicalTrials.gov
and WHO ICTRP (World Health Organization International
Clinical Trials Registry Platform). After completion of manually
removingduplicate references therewere 11,953 references.We ex-
cluded 11,914 clearly irrelevant references through reading the ab-
stracts. We sought 42 references in full text for further assessment.
We did not identify any additional references to trials by searching
the trial registry. We excluded 13 references (11 studies or com-
ments) because of the reasons mentioned in the Characteristics
of excluded studies tables and Excluded studies. We excluded five
references (three trials) which were protocols of ongoing trials with
no interim results available. Thirteen trials (24 references) met the
inclusion criteria and were included in this review (Aoyama 2014;
Cai 2011; Chen Hu 2012; Deng 2009; Hayashi 2005; Hu 2015;
Huscher 2005; Kim 2013; Kim 2015; Kitano 2002; Lee 2005;
Sakuramoto 2013; Takiguchi 2013). The reference flow diagram
is shown in Figure 1.
11Laparoscopic versus open gastrectomy for gastric cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
The thirteen trials compared laparoscopic with open gastrectomy
(Aoyama 2014; Cai 2011; Chen Hu 2012; Deng 2009; Hayashi
2005; Hu 2015; Huscher 2005; Kim 2013; Kim 2015; Kitano
2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013). Twelve
of the trials were two-armed RCTs (Aoyama 2014; Cai 2011;
Deng 2009; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2013;
Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi
2013). The thirteenth was a four-armed trial (Chen Hu 2012).
Two of the arms involved laparoscopic surgery (fast-track laparo-
scopic gastrectomy versus standard procedure laparoscopic gastrec-
tomy) and two arms involved open gastrectomy (fast-track laparo-
scopic gastrectomy versus standard procedure laparoscopic gastrec-
tomy). The exact tumour stages included for each trial are reported
in the Characteristics of included studies tables. Broadly, five trials
included patients with early stage gastric cancer (Hayashi 2005;
Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013), three
trials included patients with only advanced gastric cancer (Cai
2011; Kim 2013; Hu 2015), four trials included patients with
early or advanced gastric cancer, a wide range of cancer staging
(Aoyama 2014; Chen Hu 2012; Huscher 2005; Kim 2015), and
one trial did not specify the cancer staging of included patients
(Deng 2009).
Four of the trials included patients with an ASA risk score of III
(Cai 2011; Hu 2015; Huscher 2005; Kim 2015), one trial did
not include patients with ASA risk score III (Sakuramoto 2013),
and the remaining eight trials did not specify their inclusion or
exclusion (Aoyama 2014; Chen Hu 2012; Deng 2009; Hayashi
2005; Kim 2013; Kitano 2002; Lee 2005; Takiguchi 2013). None
of the 13 trials specifically stated the inclusion or exclusion of
patients with a BMI greater than 30.
Ten of the studies used laparoscopy-assisted gastrectomy (Aoyama
2014; Cai 2011; Chen Hu 2012; Hayashi 2005; Kim 2013;
Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi
2013), with three potentially using the totally laparoscopicmethod
(Deng 2009; Hu 2015; Huscher 2005). There was no mention of
an incision to remove the specimen in these trials, and the proce-
dure was termed laparoscopic gastrectomy in these trials. However,
it should be noted that some trials which were really laparoscopic-
assisted gastrectomy (based on the description of the procedure)
reported the procedure as laparoscopic gastrectomy. So, it is not
clear whether any of the trials used totally laparoscopic gastrec-
tomy.
Twelve of the trials involved patients in whom subtotal (dis-
tal) gastrectomy was performed (Aoyama 2014; Chen Hu 2012;
Deng 2009; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2013;
Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi
2013); in Cai 2011, proximal, distal or total gastrectomy was per-
formed. D1 nodal dissection was performed in both groups in one
trial (Hayashi 2005). D2 nodal dissection was performed in both
groups in four trials (Cai 2011; Deng 2009;Hu 2015; Kim 2013).
D1 or more nodal dissections were performed in both groups in
three trials (Aoyama 2014; Huscher 2005; Kim 2015). In two tri-
als, selected groups of lymph nodes were dissected in both groups
(Sakuramoto 2013; Takiguchi 2013). In one trial, selected nodes
were dissected in the laparoscopic group, while D2 nodal dissec-
tion was performed in the open group (Lee 2005). Information on
nodal dissection was not available in two trials (Chen Hu 2012;
Kitano 2002). Seven of the trials used the Billroth I method of
anastomosis alone (Aoyama 2014; Deng 2009; Hayashi 2005;
Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013), four
of the trials used either the Billroth I or II anastomosis, Roux en Y
anastomosis, oesophagogastrostomy or oesophageal jejunostomy
(Cai 2011; Chen Hu 2012; Huscher 2005; Kim 2015), and two
did not state the method of anastomosis used (Hu 2015; Kim
2013). Five trials used staples as the anastomotic method (Aoyama
2014; Hayashi 2005; Lee 2005; Sakuramoto 2013; Takiguchi
2013). In the remaining trials, either a combination of stapler and
hand-sewn anastomosis were used (Huscher 2005), or the infor-
mation on stapler versus hand-sewn anastomosis was not available
(Cai 2011; ChenHu 2012;Deng 2009;Hu 2015; Kim2013; Kim
2015; Kitano 2002). Drains were routinely used in both groups in
one trial (Sakuramoto 2013), and no routine drains were used in
either group in one trial (Aoyama 2014). In one 2 x 2 factorial trial
in which the safety and effectiveness of laparoscopic versus open
gastrectomy and fast-track surgery versus conventional surgery,
drains were used in participants who underwent fast-track surgery
in both the laparoscopic and open groups (Chen Hu 2012). Two
trials reported drains being used in the laparoscopic gastrectomy
group, but did not report whether drains were used routinely in
the open gastrectomy group (Lee 2005; Takiguchi 2013). The in-
formation on drain use was not available in the remaining trials
(Cai 2011; Deng 2009; Hayashi 2005; Hu 2015; Huscher 2005;
Kim 2013; Kim 2015; Kitano 2002).
The follow-up period was not available for one trial (Hu 2015).
The follow-up period in the remaining trials were as follows.
• Until discharge (Deng 2009; Sakuramoto 2013)
• 30 days (Aoyama 2014; Chen Hu 2012; Kim 2013; Kim
2015).
• 14 months (Lee 2005); 22 months (Cai 2011); 26 months
(Kitano 2002).
• 42 months (Hayashi 2005); 52 months (Huscher 2005); 60
months (Takiguchi 2013).
In total, 2794 participants were randomised in the 13 trials in-
cluded in this review. One trial which included 53 participants
did not contribute any data for this review, because none of the
outcomes included in the review were reported (Deng 2009). Two
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hundred and thirteen participants were excluded in the remaining
12 trials that contributed data, leaving a total of 2528 participants
for whom data were available. Of these 2528 participants, 1288
were randomised to laparoscopic gastrectomy and 1240 to open
gastrectomy (Aoyama 2014; Cai 2011; Chen Hu 2012; Hayashi
2005; Hu 2015; Huscher 2005; Kim 2013; Kim 2015; Kitano
2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013).
Excluded studies
We excluded a total of 13 references (11 studies or comments).
We excluded three references because they were reports of a ’quasi-
randomised’ control trial in which block allocation equivalent to
alternate assignment was used (Kim 2008). We excluded two ref-
erences because they were comments on Kim 2008 (Kim 2009;
Liakakos 2009), and we excluded one reference because it was an
editorial (Kanellos 2009). We excluded seven references because
they were not RCTs (Han 2014; Kawamura 2008; Lee 2008; Lee
2009; Li 2014; Lin 2014; Sakuramoto 2009).
We excluded five other references because they were protocols for
three trials which have not yet reported the results (Haverkamp
2015; Straatman 2015; Yoshikawa 2012). A summary of these
trials is reported in Characteristics of ongoing studies.
Risk of bias in included studies
All the trials were at unclear or high risk of bias as shown in Figure
2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Four trials were free from selection bias (Aoyama 2014; Kim 2013;
Kim 2015; Sakuramoto 2013). These trials had a low risk of bias
in random sequence generation and allocation concealment. The
remaining trials had unclear risk of bias in at least one of the aspects
of random sequence generation or allocation concealment.
Blinding
Seven of the trials were at unclear risk of performance bias because
of a lack of reported information (Aoyama 2014; Cai 2011; Deng
2009; Huscher 2005; Kim 2015; Kitano 2002; Lee 2005), with
the remaining six being at high risk of performance bias, with
patients and healthcare providers not being blinded (Chen Hu
2012; Hayashi 2005; Hu 2015; Kim 2013; Sakuramoto 2013;
Takiguchi 2013).
Ten of the trials were at unclear risk of detection bias because of a
lack of reported information (Aoyama 2014; Cai 2011; Chen Hu
2012; Deng 2009; Hayashi 2005; Huscher 2005; Kim 2013; Kim
2015; Kitano 2002; Lee 2005), with the remaining three being
at high risk of detection bias, with outcome assessors not being
blinded (Hu 2015; Sakuramoto 2013; Takiguchi 2013).
Incomplete outcome data
We classified three trials at low risk of attrition bias as they
described no post-randomisation drop-outs (Hayashi 2005; Hu
2015; Takiguchi 2013). Four trials were at unclear risk of attrition
bias as the reports did not describe the participant flow clearly
(Aoyama 2014; Deng 2009; Kitano 2002; Lee 2005). Six trials
were at high risk of attrition bias as they had post-randomisa-
tion drop-outs which were likely to affect the effect estimates (Cai
2011; Chen Hu 2012; Huscher 2005; Kim 2013; Kim 2015;
Sakuramoto 2013).
Selective reporting
We classified six of the trials at low risk of reporting bias, with
both postoperative mortality and morbidity reported (Aoyama
2014; Cai 2011; Chen Hu 2012; Hayashi 2005; Huscher 2005;
Sakuramoto 2013). We classified seven of the trials at high risk of
reporting bias, as one or both of these were not reported (Deng
2009; Hu 2015; Kim 2013; Kim 2015; Kitano 2002; Lee 2005;
Takiguchi 2013).
Other potential sources of bias
In one trial, a more extensive procedure (subtotal gastrectomy)
was performed in open gastrectomy group compared to laparo-
scopic group (distal gastrectomy) (Lee 2005). This could poten-
tially favour the laparoscopic group in terms of decreased compli-
cations, but favour the open group in terms of decreased long-term
recurrence and mortality. We did not detect any other sources of
bias in the remaining trials.
Effects of interventions
See: Summary of findings for the main comparison
Laparoscopic gastrectomy compared to open gastrectomy for
gastric cancer (primary outcomes); Summary of findings 2
Laparoscopic gastrectomy compared to open gastrectomy for
gastric cancer (secondary outcomes)
The outcomes reported in these trials were: short-term mortality,
long-term mortality, serious adverse events within three months,
short-term recurrence, long-term recurrence, adverse eventswithin
three months, blood transfusion during or within a week of
surgery, quantity of perioperative blood transfused, length of hos-
pital stay, positive resection margins on histopathology, and num-
ber of lymph nodes harvested. The remaining outcomes of interest
in the review, i.e. short- and medium-term health-related quality
of life, time to return to normal activity, and time to return to
work were not reported in any of the trials. The results are partially
summarised in Summary of findings for themain comparison and
Summary of findings 2.
Short-term mortality
Eleven trials reported short-term mortality which is defined as
mortality in hospital or within thirty days of treatment (Aoyama
2014; Cai 2011; Chen Hu 2012; Hayashi 2005; Hu 2015;
Huscher 2005; Kim 2015; Kitano 2002; Lee 2005; Sakuramoto
2013; Takiguchi 2013). We pooled the trials using a fixed-effect
model. There was no significant difference in the proportion of
participants who died within 30 days of treatment between laparo-
scopic gastrectomy (7/1188: adjusted proportion (based on meta-
analysis) = 0.6%) and open gastrectomy (4/1447: 0.3%) (RR 1.60,
95% CI 0.50 to 5.10; participants = 2335; studies = 11; I2 = 0%;
low quality evidence) (Analysis 1.1; Summary of findings for the
main comparison). There was no change to the conclusions when
we used a random-effects model or when we calculated the risk
difference (RD 0.00, 95% CI -0.01 to 0.01; participants = 2335;
studies = 11; I2 = 0%).
Long-term mortality
Three trials reported long-term mortality (Cai 2011; Huscher
2005; Takiguchi 2013). In one of these trials, all the participants
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were alive after a follow-up period of 60months (Takiguchi 2013).
We pooled the trials using a fixed-effect model. There was no
significant difference in long-term mortality between the groups
(HR 0.94, 95% CI 0.70 to 1.25; participants = 195; studies = 3;
I2 = 0%; very low quality evidence) (Analysis 1.2; Summary of
findings for the main comparison). There was no change to the
conclusionswhenwe used a random-effectsmodel. Approximately
55% to 60% of participants were alive after about 52 months
(Huscher 2005).
Serious adverse events within three months
Eight trials reported serious adverse events within three months
of treatment (Aoyama 2014; Cai 2011; Chen Hu 2012; Hayashi
2005; Huscher 2005; Kitano 2002; Lee 2005; Sakuramoto 2013).
The serious adverse events in the trials included anastomotic leak-
age, anastomotic stenosis requiring balloon dilatation, pancreatic
fistula, pancreatic injury, small bowel volvulus requiring adhesiol-
ysis, bleeding requiring reoperation, abdominal abscess, myocar-
dial infarction, acute respiratory distress syndrome, pleural effu-
sion requiring puncture, and pneumonia. The type of serious ad-
verse events were similar in nature between the groups. We pooled
the trials using a fixed-effect model. There was no significant dif-
ference in the proportion of participants who suffered a serious
adverse event between laparoscopic gastrectomy (7/216: adjusted
proportion = 3.6%) and open gastrectomy (13/216: 6%) within
three months of treatment (RR 0.60, 95% CI 0.27 to 1.34; par-
ticipants = 432; studies = 8; I2 = 0%; very low quality evidence)
(Analysis 1.3; Summary of findings for the main comparison).
There was no change to the conclusions when we used a random-
effects model or when we calculated risk difference.
Health-related quality of life
Short- and medium-term health-related quality of life were not
reported in any of the trials.
Short-term recurrence
Three trials reported short-term recurrence, which is defined as
local recurrence, surgical wound recurrence or distal metastases
within six months (Hayashi 2005; Kitano 2002; Lee 2005). No
events were reported for either laparoscopic (52 participants) or
open gastrectomy (51 participants). Therefore, we could not cal-
culate an effect estimate (participants = 103; studies = 3) (Analysis
1.4).
Long-term recurrence
Four trials reported long-term recurrence (> six months) (Hayashi
2005; Huscher 2005; Kitano 2002; Lee 2005). Three of these
three trials did not report any recurrence in either group (Hayashi
2005; Kitano 2002; Lee 2005). There was no significant differ-
ence in the hazard ratio for recurrence more than six months after
treatment between the two groups (HR 0.95, 95% CI 0.70 to
1.30; participants = 160; studies = 4; very low quality evidence)
(Analysis 1.5; Summary of findings 2). Since only one trial con-
tributed to the analysis, the issue of fixed-effect versus random-
effectsmeta-analysis and assessment of heterogeneity did not arise.
Adverse events within three months
Eleven trials reported adverse events within three months of treat-
ment (Aoyama 2014; Cai 2011; Chen Hu 2012; Hayashi 2005;
Hu 2015;Huscher 2005; Kim 2013; Kim 2015; Kitano 2002; Lee
2005; Sakuramoto 2013). We pooled the trials using a random-
effects model. There were significantly fewer adverse events fol-
lowing laparoscopic gastrectomy (204/268: adjusted proportion
= 16.1%) versus open gastrectomy (253/1222: 20.7%) (RR 0.78,
95% CI 0.60 to 1.01; participants = 2490; studies = 11; I2 = 38%;
very low quality evidence) (Analysis 1.6: Summary of findings 2).
However, on using the fixed-effect model, there was no statisti-
cally significant difference between the groups (RR 0.78, 95%
CI 0.66 to 0.92; participants = 2490; studies = 11; I2 = 38%).
Two large trials had narrow confidence intervals and had results
in opposite directions, and this may account for the differences
between the fixed-effect and random-effects models. In addition,
we performed a sensitivity analysis excluding Lee 2005, in which
the laparoscopic group underwent a less invasive procedure than
the open group. There was no change in the results by excluding
this trial.
Blood transfusion during or within a week of surgery
Two trials reported the proportion of patients requiring blood
transfusion during or within a week of surgery (Aoyama 2014;
Takiguchi 2013).None of the participants in either group in either
of the trials required a blood transfusion. Therefore, we could not
estimate an effect estimate (participants = 66; studies = 2) (Analysis
1.7). Since both trials reported the mean and standard deviation,
we did not perform any sensitivity analysis excluding studies in
which standard deviation was imputed.
Quantity of perioperative blood transfused
Two trials reported quantity of perioperative blood transfused (Cai
2011; Lee 2005): Lee 2005 reported the number of units of blood
transfused; and Cai 2011 reported the amount of blood transfused
in SI units. We pooled the trials using a fixed-effect model. There
was no significant difference in the amount of blood transfused
between the laparoscopic and open gastrectomy groups (SMD
0.05, 95% CI -0.27 to 0.38; participants = 143; studies = 2; I
2 = 0%; very low quality evidence) (Analysis 1.8; Summary of
findings 2). There was no change to the conclusions when we used
a random-effects model.
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Length of hospital stay
Eight trials reported length of hospital stay (Cai 2011; Chen Hu
2012; Hayashi 2005; Huscher 2005; Kitano 2002; Lee 2005;
Sakuramoto 2013; Takiguchi 2013). The length of hospital stay
was significantly shorter in the laparoscopic group than the open
group (MD -1.38 days, 95%CI -2.57 to -0.19; participants = 444;
studies = 8; I2 = 76%; very lowquality evidence) using the random-
effects model (Analysis 1.9; Summary of findings 2). There was
substantial heterogeneity as noted by I2 of 76% and Chi2 test
for heterogeneity P value of 0.0001. Using the fixed-effect model
did not alter the results (MD -0.86 days, 95% CI -1.27 to -0.44;
participants = 444; studies = 8; I2 = 76%). In two trials, median
hospital stay rather thanmeanhospital staywas reported (ChenHu
2012; Takiguchi 2013). In Takiguchi 2013, the standard deviation
was calculated from the P value, while in Chen Hu 2012, the
standard deviation was imputed as the highest standard deviation
from the remaining trials. Excluding these two trials, there was no
statistically significant difference between the two groups (MD -
1.82 days, 95% CI -3.72 to 0.07; participants = 319; studies =
6; I2 = 83%) using the random-effects model, although there was
still a statistically significant difference between the groups using
the fixed-effect model (MD -0.68 days, 95% CI -1.31 to -0.06;
participants = 319; studies = 6; I2 = 83%). The exclusion of Lee
2005, in which the laparoscopic group underwent a less invasive
procedure did not alter the results.
Time to return to normal activity
This outcome was not reported in any of the trials.
Time to return to work
This outcome was not reported in any of the trials.
Positive resection margins at histopathological
examination
One trial reported the number of patients with positive resec-
tion margins at histopathological examination (Kitano 2002). No
events were reported for either laparoscopic or open gastrectomy.
Therefore, we could not calculate an effect estimate (participants
= 28; study = 1) (Analysis 1.10).
Number of lymph nodes harvested
Nine trials reported the number of lymph nodes harvested
(Aoyama 2014; Cai 2011; ChenHu2012;Hayashi 2005;Huscher
2005; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi
2013). We analysed the trials using a fixed-effect model. There
was no significant difference in the number of lymph nodes har-
vested between the two groups (MD -0.63, 95% CI -1.51 to 0.25;
participants = 472; studies = 9; I2 = 40%; very low quality ev-
idence) (Analysis 1.11; Summary of findings 2). There was no
change to the conclusions when we used a random-effects model.
Since higher numbers of lymph nodes harvested is a better sur-
gical marker, we switched the direction of the X-axis in Analysis
1.11, with trials to the left of the equivalence line favouring open
gastrectomy. The mean or standard deviation or both were cal-
culated from other information such as median, standard error,
or P value or imputed from the maximum standard deviation in
the included studies in four trials (Aoyama 2014; Chen Hu 2012;
Huscher 2005; Takiguchi 2013). Excluding these trials did not
alter the conclusions (MD -0.62, 95% CI -1.55 to 0.31; partici-
pants = 262; studies = 5; I2 = 70%).
Subgroup analysis
Of the planned subgroup analyses for the primary outcomes, only
two were possible.
1. Different cancer stages (early gastric cancer and advanced
gastric cancer). There was no short-term mortality or long-term
mortality in laparoscopic or open gastrectomy groups in the early
gastric cancer subgroup. So, we could not perform tests for
subgroup differences (Analysis 2.1; Analysis 2.2). The test for
subgroup differences was not statistically significant for subgroup
analysis of serious adverse events, and there was a good overlap of
confidence interval between the effect estimates of the different
subgroups (Analysis 2.3).
2. Different types of gastrectomy (subtotal versus total
gastrectomy). Of the 13 trials, 12 trials reported the use of
subtotal gastrectomy (Aoyama 2014; Chen Hu 2012; Deng
2009; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2013; Kim
2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi
2013). In Cai 2011, a mixture of different types of gastrectomies
was performed. No separate data were available for the different
types of gastrectomies. Excluding this trial did not alter the
results (Analysis 2.4; Analysis 2.5; Analysis 2.6).
The remaining subgroup analyses were not possible for the fol-
lowing reasons.
1. Totally laparoscopic and laparoscopy-assisted gastrectomy:
it was not clear whether any of the trials used totally laparoscopic
gastrectomy.
2. Different cancer stages (node-positive and node-negative
gastric cancer): none of the trials reported the results separately
for different nodal status.
3. Different methods of anastomoses (stapler versus hand-
sewn anastomoses): five trials used staples as the anastomotic
method (Aoyama 2014; Hayashi 2005; Lee 2005; Sakuramoto
2013; Takiguchi 2013). In the remaining trials, either a
combination of stapler and hand-sewn anastomosis were used
(Huscher 2005), or the information on stapler versus hand-sewn
anastomosis was not available (Cai 2011; Chen Hu 2012; Deng
2009; Hu 2015; Kim 2013; Kim 2015; Kitano 2002).
4. People with different anaesthetic risk (ASA I (a healthy
person) or ASA II (a person with mild systemic disease) versus
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ASA III or more (a person with severe systemic disease or worse):
none of the trials that included ASA III participants reported the
results separately for ASA III participants.
5. Different BMI (healthy weight (BMI 18.5 to 25) versus
overweight or obese (BMI 25 or greater)): none of the trials
reported results separately for people with different BMI ranges.
Sensitivity analysis
The sensitivity analysis excluding trials in which either mean or
standard deviation or both were imputed have been presented in
the individual outcomes. Another sensitivity analysis excluding
the trial in which the laparoscopic group underwent less invasive
distal gastrectomy, and the open group underwent more invasive
subtotal gastrectomy, did not alter the results. We performed the
remaining sensitivity analyses for the following reasons.
1. All trials were at unclear or high risk of bias.
2. No cluster-RCTs were included.
3. The only multi-armed trial included was investigating fast-
track surgery. Since this variable was not of interest to this
review, we considered the trial a two-arm trial.
Reporting bias
Only two outcomes had 10 or more trials, namely, short-term
mortality and adverse events. We did not assess reporting bias
using a funnel plot in the remaining comparisons. In the outcome,
short-term mortality, only three trials had one or more events in
at least one of the groups (Hu 2015; Huscher 2005; Kim 2015).
So, we did not assess reporting bias using a funnel plot for short-
term mortality either. Visual inspection revealed that studies with
large variance were more prevalent in the laparoscopic group than
the open group, suggesting potential reporting bias. However, the
Egger’s test was not statistically significant (P = 0.3144).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Laparoscopic gastrectomy compared to open gastrectomy for gastric cancer (secondary outcomes)
Patient or population: patients with gastric cancer
Settings: secondary or tertiary setting
Intervention: laparoscopic gastrectomy
Comparison: open gastrectomy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Open gastrectomy Laparoscopic gastrec-
tomy
Long-term recurrence
(maximal follow-up)
450 per 1000 433 per 1000
(342 to 540)
HR 0.95
(0.70 to 1.30)
162
(4 studies)
⊕©©©
very low1,2
Proportion with an ad-
verse event (<3months)
207 per 1000 161 per 1000
(124 to 209)
RR 0.78
(0.60 to 1.01)
2490
(11 studies)
⊕©©©
very low1,3
Quantity of perioperative
blood transfused
The mean quantity of pe-
rioperative blood trans-
fused in the control
groups was
0.08 litres
The mean quantity of pe-
rioperative blood trans-
fused in the intervention
groups was
0.05 standard deviations
higher
(0.27 lower to 0.38
higher)
143
(2 studies)
⊕©©©
very low1,2
SMD 0.05 (-0.27 to 0.38)
Length of hospital stay The mean length of hos-
pital stay in the interven-
tion groups was
1.82 lower
(3.72 lower to 0.07
higher)
319
(6 studies)
⊕©©©
very low1,2,4
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Number of lymph nodes
harvested
The mean number of
lymph nodes harvested in
the control groups was
27
The mean number of
lymph nodes harvested
in the intervention groups
was
0.63 lower
(1.51 lower to 0.25
higher)
472
(9 studies)
⊕©©©
very low1,4
There were no events in either group for short-term recurrence (103 participants (3 studies)), proportion requiring blood transfusion (66 participants (2 studies)), proportion with positive
resection margin (incomplete cancer resection) (14 participants (1 study))
None of the trials reported on measures of earlier postoperative recovery such as time to return to normal activity or time to return to work
*The basis for the assumed risk was the mean control group proportion. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; HR: hazard ratio; RR: risk ratio; SMD: standardised mean difference.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 There was unclear or high risk of bias within the trials (downgraded by two levels). Please see Figure 2 and Figure 3 which show this.
2 The confidence intervals were wide (overlaps no effect and clinically significantly effect) and the sample size was small (downgraded
by two levels).
3 Visual inspection revealed that studies with large variance were more in the favour of laparoscopic group than the open group,
suggesting potential reporting bias (downgraded by one level).
4 Significant heterogeneity detected in the studies by the I2 values and Chi2 test (downgraded by two levels).
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D I S C U S S I O N
Summary of main results
In this review, we compared laparoscopic versus open gastrectomy
for people with non-metastatic gastric cancer. There were no sta-
tistically significant differences in short-termmortality, long-term
mortality, proportion of people with serious adverse events within
three months of surgery, proportion of people with recurrence
within six months, proportion of people with recurrence after six
months, proportion of people requiring blood transfusion during
or within a week of surgery, proportion of people with any ad-
verse event within three months of surgery, quantity of perioper-
ative blood transfused, proportion of people with positive resec-
tion margins at histopathological examination, or in the number
of lymph nodes harvested by each technique. None of the trials
reported patient oriented outcomes such as health-related quality
of life, time to return to normal activity, or time to return to work.
Short-termmortality was reported in 2335 participants. Based on
the number of participants included and the confidence intervals
obtained by calculating the risk difference, it appears that there is
no difference between laparoscopic and open gastrectomy in terms
of mortality (i.e. this is lack of effect rather than lack of evidence
of effect), although the risk of bias in the trials, mainly due to
exclusion of participants who did not receive the planned treat-
ment, introduces some doubt on this issue. Differences in serious
adverse events within three months, length of hospital stay, long-
term recurrence, and long-term mortality (which are the other
major outcomes of interest for patients and healthcare funders)
cannot be ruled out since the confidence intervals were wide.
Overall completeness and applicability of
evidence
This review included participants undergoing either laparoscopic
or open gastrectomy for gastric cancer. Although the American So-
ciety of Anesthesiologists (ASA) status was not reported in many
trials, all the participants must have been fit for major surgery
since both arms involve major surgeries. Thus, the results of this
review are applicable only to patients with gastric cancer, with a
variety of stages from early to advanced cancer, and are not appli-
cable to patients who are not suitable for surgery either because
of their anaesthetic risk or because of the location or presence of
metastatic disease. It should also be noted that the results apply
only to laparoscopy-assisted distal gastrectomy since it was not
clear whether three trials that did not report a small laparotomy
incision performed totally laparoscopic gastrectomy, and because
most trials in this review included participants undergoing distal
gastrectomy.
Quality of the evidence
All the trials were at unclear or high risk of bias. Selection bias and
funding bias were at unclear or low risk of bias in all trials. Those
trials with unclear risk of bias were generally due to a lack of clear
information. We graded both performance and detection bias as
high risk of bias in a significant number of trials, with issues in
blinding of the healthcare providers responsible for these. There
was significant bias due to missing outcomes in the trials, with six
of the studies at high risk of bias because of post-randomisation
drop-outs. This canbe easily avoided by using an intention-to-treat
analysis, which involves reporting the outcomes for all randomised
patients even if they do not receive the relevant treatment. There
was significant selective reporting bias in the trials, with seven of
the studies at high risk of bias generally because morbidity was not
reported adequately. Severity of the outcomes is more important
than stating whether an adverse event occurred.
There was significant heterogeneity in length of hospital stay. Be-
cause of the few trials included in each subgroup, the subgroup
analysis may not be reliable and multiple subgroup analyses can
lead to spurious results. A potential reason for this heterogeneity
may be different criteria for discharging patients who had under-
gone gastrectomy in different trials. The trials did not report this
sufficiently to determine if this was the reason for the differences
in effect estimates in trials.
There was imprecision in many outcomes despite the inclusion of
more than 2500 participants in the various trials included in this
review. This was because of selective outcome reporting with trials
not reporting even important outcomes such as serious adverse
events.
Despite the shortcomings in the studies included in this review,
these studies constitute the best level of evidence that is currently
available. Overall, the evidence from this systematic review is more
trustworthy than observational studies and expert opinions. This
is because observational studies contain inherent bias. It is quite
possible that people with lower tumour burden will be selected to
undergo laparoscopic gastrectomywhile thosewith greater tumour
burden will undergo open gastrectomy. This will lead to bias due
to confounding in observational studies.
Potential biases in the review process
We followed the Cochrane Handbook for Systematic Reviews of In-
terventions for this review (Higgins 2011). There were no language,
publication status, or sample size restrictions. Thus, we minimised
the bias due to selection of trials. There was suspicion of report-
ing bias for adverse events by visual inspection of funnel plots,
although this was not substantiated by Egger’s test. Since there
was no restriction on the publication date, we included trials from
the pre-mandatory trial registration era. There is a possibility that
some of the trials were not reported because of the direction of
results. However, we have to be pragmatic and accept that it will
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be difficult to obtain useful data from these trials after such a long
period of time. So, we have to arrive at conclusions based on the
trials which have been published or reported in conferences. We
calculated the hazard ratio for long-term mortality and long-term
recurrence usingmethods suggested in Parmar 1998. This assumes
constant proportional hazards. From the Kaplan-Meier curves in
the studies, the proportional hazards appeared constant for both
long-term mortality and long-term recurrence.
Agreements and disagreements with other
studies or reviews
This is the first Cochrane review to assess laparoscopic versus open
gastrectomy for gastric cancer. We identified three previous sys-
tematic reviews of RCTs on this topic (Jiang 2013; Liang 2011;
Sun 2012). The authors of these systematic reviews appear to sug-
gest that laparoscopic surgery is better than open surgery for one
ormore short-term outcomes, in particular, length of hospital stay.
However, we are more cautious in concluding that laparoscopic
surgery is better than open surgery because of the risk of bias in the
studies included and the heterogeneity in the length of hospital
stay.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on low quality evidence, there is no difference in short-term
mortality between laparoscopic and open gastrectomy. Based on
very low quality evidence, there is no evidence for any differences
in short-term or long-term outcomes between laparoscopic and
open gastrectomy. However, the data are sparse and the confidence
intervals were wide suggesting that significant benefits or harms
of laparoscopic gastrectomy cannot be ruled out.
Implications for research
Several trials are currently being conducted and interim results of
these trials have been included in this review. These trials need
to perform intention-to-treat analysis to ensure that the results
are reliable and report the results according to the CONSORT
statement (CONSORT 2010). If new trials are designed, they
need to be designed according to the SPIRIT statement (SPIRIT
2013).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aoyama 2014
Methods Randomised controlled trial
Participants Country: Japan
Number randomised: 26
Post-randomisation drop-outs: not stated
Number analysed: 26
Average age: 65 years
Females: 12 (46.2%)
Method of Anastamosis: Billroth-I; stapler
Type of gastrectomy: Subtotal gastrectomy
Cancer stage: Early or advanced stage (T1−2N0−1)
Totally laparoscopic or LAG: LAG
Inclusion criteria
Patients undergoing distal gastrectomy for stage I gastric cancer
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 13)
Further details: 5 or 6 ports; incision ≤ 6 cm
Group 2: open gastrectomy (n = 13)
Further details: Upper midline incision (xiphoid to umbilicus)
Nodes dissected and drain use: D1 or more nodal dissection; no routine drain
Outcomes The outcomes reported were short-term mortality, complications, and lymph nodes
harvested
Notes Conversion to open gastrectomy: 0/13 (0%)
Follow-up period: 30 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients are randomized to either the ODG arm
or the LADG arm by minimization method balancing
the arms with institution and clinical stage (IA/IB)”
Comment: This information was not available
Allocation concealment (selection bias) Low risk Quote: “After the confirmation of the eligibility criteria,
registration is made by telephone, fax or web-based sys-
tem to the JCOG Data Center. Patients are randomized
to either the ODG arm or the LADG arm by minimiza-
tionmethodbalancing the armswith institution and clin-
ical stage (IA/IB)”
Comment: This information was not available
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Aoyama 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: This information was not available
Selective reporting (reporting bias) Low risk Comment: Postoperative mortality and morbidity were
reported
Other bias Low risk Comment: No other source of bias was identified
Cai 2011
Methods Randomised controlled trial
Participants Country: China
Number randomised: 123
Post-randomisation drop-outs: 27 (22%)
Number analysed: 96
Average age: 60 years
Females: 20 (20.8%)
Method of Anastamosis: Billroth-I, Billroth-II, oesophagogastrostomy and oesophageal
jejunostomy; hand-sewn or stapler anastomosis not stated
Type of gastrectomy: Proximal, distal, or total gastrectomy
Cancer stage: Advanced stage (T2−3Nnotstated )
Totally laparoscopic or LAG: LAG
Inclusion criteria
Patients requiring gastrectomy for gastric cancer
Exclusion criteria
1. Patients needed thoraco-abdominal surgery
2. Patients with other malignant tumours
3. Patients with upper abdominal large operation history who cannot be fitted for
LAG
4. Patients with gastric stump cancer and recurrent cancer
5. Patients with a surgical risk greater than ASA grade III
6. Patients with operative cardiovascular risk greater than New York Heart
Association grade II
7. Severe liver disease (Child B or C) and renal dysfunction
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 49)
Further details: 5 ports; upper midline incision about 6 cm
Group 2: open gastrectomy (n = 47)
Further details: Upper midline incision (20 cm)
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Cai 2011 (Continued)
Nodes dissected and drain use: D2 nodal dissection; drain use not stated
Outcomes The outcomes reported were short-term mortality, complications, lymph nodes har-
vested, length of hospital stay, and long-term mortality
Notes Conversion to open gastrectomy: 2/61 (3.3%)
Follow-up period: 22 months
Reasons for post-randomisation drop-outs: not clearly reported. The authors state that
they performed a subgroup analysis of patients with advanced stage cancer only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Unclear risk Comment: This information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Comment: Postoperative mortality and morbidity were
reported
Other bias Low risk Comment: No other source of bias was identified
Chen Hu 2012
Methods Randomised controlled trial
Participants Country: China
Number randomised: 88
Post-randomisation drop-outs: 5 (5.7%)
Number analysed: 83
Average age: 63 years
Females: 41 (49.4%)
Method of Anastamosis: Billroth-I or Billroth-II; hand-sewn or stapler anastomosis not
stated
Type of gastrectomy: Subtotal gastrectomy
Cancer stage: Early or advanced stage (T1−4Nnotstated )
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Chen Hu 2012 (Continued)
Totally laparoscopic or LAG: LAG
Inclusion criteria
1. Age 25-75 years old
2. Male or female
3. Diagnosis confirmed by endoscopic biopsy
4. No lymph node or distant metastasis diagnosed by preoperative abdominal
computed tomography
5. No history of autoimmune or severe cardiopulmonary diseases
6. No preoperative radiotherapy or chemotherapy
7. No digestive obstruction, perioperative blood or albumin infusion, combined
intraoperative evisceration
8. Acceptance by the patients and their families
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 41)
Further details: number of ports not stated; upper midline incision (5 to 8 cm)
Group 2: open gastrectomy (n = 44)
Further details: Upper midline incision (xiphoid to umbilicus or 2 cm below umbilicus)
Nodes dissected and drain use: Nodal dissection not stated; routine drains were used in
the part of group who underwent fast-track surgery
Outcomes The outcomes reported were short-term mortality, complications, lymph nodes har-
vested, and hospital stay
Notes Conversion to open gastrectomy: not reported
Follow-up period: 30 days
Reasons for post-randomisation drop-outs: withdrew consent (3); lost to follow-up 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Unclear risk Comment: This information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Blinding of the surgeons and nurses was not
feasible. Therefore, two specially trained doctors blinded
to patients’ allocated treatment group were in charge for
assessing postoperative outcomes and follow-up”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Blinding of the surgeons and nurses was not
feasible. Therefore, two specially trained doctors blinded
to patients’ allocated treatment group were in charge for
assessing postoperative outcomes and follow-up”
Comment: It was not clear whether outcomes such as
decision to discharge were made by the blinded outcome
assessor
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Chen Hu 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Comment: Postoperative mortality and morbidity were
reported
Other bias Low risk Comment: No other source of bias was identified
Deng 2009
Methods Randomised controlled trial
Participants Country: China
Number randomised: 53
Post-randomisation drop-outs: not stated
Number analysed: 53
Average age: 51 years
Females: 27 (50.9%)
Method of Anastamosis: Billroth-I; hand-sewn or stapler anastomosis not stated
Type of gastrectomy: Subtotal gastrectomy
Cancer stage: not stated (TnotstatedNnotstated )
Totally laparoscopic or LAG: Possibly totally laparoscopic
Inclusion criteria
Patients undergoing distal gastrectomy for gastric cancer
Exclusion criteria
1. Preoperative chemotherapy
2. Severe metabolic disorders
3. Endocrine or immune system diseases
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 26)
Further details: 5 ports
Group 2: open gastrectomy (n = 27)
Further details: Upper midline incision
Nodes dissected and drain use: D2 nodal dissection; drain use not stated
Outcomes None of the outcomes of interest were reported
Notes Conversion to open gastrectomy: not reported
Follow-up period: until discharge
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
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Deng 2009 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: This information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: This information was not available
Selective reporting (reporting bias) High risk Comment: Postoperative mortality and morbidity were
not reported
Other bias Low risk Comment: No other source of bias was identified
Hayashi 2005
Methods Randomised controlled trial
Participants Country: Japan
Number randomised: 28
Post-randomisation drop-outs: 0 (0%)
Number analysed: 28
Average age: 59 years
Females: 6 (21.4%)
Method of Anastamosis: Billroth-I; stapler
Type of gastrectomy: Subtotal gastrectomy
Cancer stage: Early stage (T1Nnotstated )
Totally laparoscopic or LAG: LAG
Inclusion criteria
Patients undergoing distal gastrectomy for early gastric cancer
Exclusion criteria
1. Cancer suitable for EMR
2. Cancer located in the upper half of the stomach
3. Age exceeding 80 years
4. Operative cardiovascular risk greater than New York Heart Association II
5. Severe liver disease (Child B or C) and renal dysfunction
6. No consent to participate in the study
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 14)
Further details: 4 ports; upper transverse incision about 6 cm
Group 2: open gastrectomy (n = 14)
Further details: Upper midline incision
Nodes dissected and drain use: D1 nodal dissection; drain use not stated
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Hayashi 2005 (Continued)
Outcomes The outcomes reported were short-term mortality, complications, lymph nodes har-
vested, length of hospital stay, and long-term mortality
Notes Conversion to open gastrectomy: 0/14 (0%)
Follow-up period: 42 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Low risk Quote: “Randomization of the patients into two groups
(LADG or ODG) was performed by the blind envelope
method on the day before surgery, and the patients were
informed of the results the same day”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Randomization of the patients into two groups
(LADG or ODG) was performed by the blind envelope
method on the day before surgery, and the patients were
informed of the results the same day”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: There were no post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Comment: Postoperative mortality and morbidity were
reported
Other bias Low risk Comment: No other source of bias was identified
Hu 2015
Methods Randomised controlled trial
Participants Country: China
Number randomised: 607
Post-randomisation drop-outs: 0 (0%)
Number analysed: 607
Average age: not stated
Females: not stated
Method of Anastamosis: no information on type of anastomosis; hand-sewn or stapler
anastomosis not stated
Type of gastrectomy: Subtotal gastrectomy
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Hu 2015 (Continued)
Cancer stage: Advanced stage (T2−4N0−3)
Totally laparoscopic or LAG: Possibly totally laparoscopic
Inclusion criteria
1. Age from over 18 to under 75 years
2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or
poorly differentiated) confirmed pathologically by endoscopic biopsy
3. cT2-4a, N0-3, M0 at preoperative evaluation according to the AJCC Cancer
Staging Manual Seventh Edition
4. Expected curative resection through distal subtotal gastrectomy with D2
lymphadenectomy
5. Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group)
scale
6. ASA score class I, II, or III
7. Written informed consent
Exclusion criteria
1. Women during pregnancy or breast-feeding
2. Severe mental disorder
3. History of previous upper abdominal surgery (except laparoscopic
cholecystectomy)
4. History of previous gastrectomy, endoscopic mucosal resection or endoscopic
submucosal dissection
5. Enlarged or bulky regional lymph node diameter over 3 cm by preoperative
imaging
6. History of other malignant disease within past five years
7. History of previous neoadjuvant chemotherapy or radiotherapy
8. History of unstable angina or myocardial infarction within past six months
9. History of cerebrovascular accident within past six months
10. History of continuous systematic administration of corticosteroids within one
month
11. Requirement of simultaneous surgery for other disease
12. Emergency surgery due to complication (bleeding, obstruction or perforation)
caused by gastric cancer
13. FEV1
50% of predicted values
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 308)
Further details: number of ports not stated
Group 2: open gastrectomy (n = 299)
Further details: Incision not stated
Nodes dissected and drain use: D2 nodal dissection; drain use not stated
Outcomes The outcomes reported were short-term mortality and complications
Notes Conversion to open gastrectomy: 14/308 (4.5%)
Follow-up period: not reported
Risk of bias
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Hu 2015 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Unclear risk Comment: This information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Masking: Open Label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Masking: Open Label”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: There were no post-randomisation drop-outs
Selective reporting (reporting bias) High risk Comment: The severity of postoperative complications
was not reported
Other bias Low risk Comment: No other source of bias was identified
Huscher 2005
Methods Randomised controlled trial
Participants Country: Italy
Number randomised: 70
Post-randomisation drop-outs: 11 (15.7%)
Number analysed: 59
Average age: 64 years
Females: 20 (33.9%)
Method of Anastamosis: Billroth-I or Billroth-II; some anastomoses by stapler and others
by hand-sewn anastomoses
Type of gastrectomy: Subtotal gastrectomy
Cancer stage: Early or advanced stage (T1−4N0−2)
Totally laparoscopic or LAG: Possibly totally laparoscopic
Inclusion criteria
Patients undergoing subtotal gastrectomy for distal gastric cancer
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 30)
Further details: 4 ports
Group 2: open gastrectomy (n = 29)
Further details: Incision not stated
Nodes dissected and drain use: D1 or D2 nodal dissection; drain use not stated
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Huscher 2005 (Continued)
Outcomes The outcomes reported were short-term mortality, complications, lymph nodes har-
vested, length of hospital stay, long-term mortality, and long-term recurrence
Notes Conversion to open gastrectomy: not reported
Follow-up period: 52 months
Reasons for post-randomisation drop-outs: extension beyond distal cancer; metastases
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Unclear risk Comment: This information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Comment: Postoperative mortality and morbidity were
reported
Other bias Low risk Comment: No other source of bias was identified
Kim 2013
Methods Randomised controlled trial
Participants Country: South Korea
Number randomised: 204
Post-randomisation drop-outs: 9 (4.4%)
Number analysed: 195
Average age: not stated
Females: not stated
Method of Anastamosis: no information on type of anastomosis; hand-sewn or stapler
anastomosis not stated
Type of gastrectomy: Subtotal gastrectomy
Cancer stage: Advanced stage (T2−4N0−3)
Totally laparoscopic or LAG: LAG
Inclusion criteria
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Kim 2013 (Continued)
1. Patients with clinically advanced stage non metastatic, histologically proven
gastric cancer (cT2-4 N0-3 M0) according to the sixth union for international cancer
control edition)
2. Aged between 20 to 80 years
Exclusion criteria
1. Participation in another trial interfering with the outcome of this study
2. Language problems
3. Lack of compliance
4. Mental inability
5. Synchronous or previous malignant disease (except curatively treated in situ
cervical cancer or curatively resected non-melanoma skin cancer)
6. Systemic administration of corticosteroids
7. Unstable angina or myocardial infarction within 6 months of the trial
8. Severe respiratory disease
9. ASA score
3
10. Previous major abdominal surgery
11. Previous chemo- or radiotherapy
12. Inadequate liver, kidney- and bone-marrow functions
13. Eastern Cooperative Oncology Group status
1
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 100)
Further details: number of ports and incision size not stated
Group 2: open gastrectomy (n = 95)
Further details: Incision not stated
Nodes dissected and drain use: D2 nodal dissection; drain use not stated
Outcomes The outcomes reported were complications
Notes Conversion to open gastrectomy: not reported
Follow-up period: 30 days
Reasons for post-randomisation drop-outs: protocol violation and withdrawal of patient
permission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization is performed as block random-
ization in fixed block sizes in a 1:1 allocation ratio us-
ing a centralized web-based randomization system (eVe-
los [http://eresearch.ncc. re.kr/eres/jsp/ereslogin.jsp])”
Allocation concealment (selection bias) Low risk Quote: “Randomization is performed as block random-
ization in fixed block sizes in a 1:1 allocation ratio us-
ing a centralized web-based randomization system (eVe-
los [http://eresearch.ncc. re.kr/eres/jsp/ereslogin.jsp])”
38Laparoscopic versus open gastrectomy for gastric cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kim 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Blinding procedures are not possible in this trial
due to the nature of the intervention”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “However blinded assessment of the primary &
secondary outcomes were provided by blinded observers”
(author replies)
Comment: It is unclear how the decision on hospital
discharge and serious adverse events were assessed (for
example, by a second surgical team)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Comment: Mortality and the severity of postoperative
complications were not reported
Other bias Low risk Comment: No other source of bias was identified
Kim 2015
Methods Randomised controlled trial
Participants Country: South Korea
Number randomised: 1416
Post-randomisation drop-outs: 160 (11.3%)
Number analysed: 1256
Average age: not stated
Females: not stated
Method of Anastamosis: Billroth-I, Billroth-II, or Roux-en-Y anastomosis; hand-sewn
or stapler anastomosis not stated
Type of gastrectomy: Subtotal gastrectomy
Cancer stage: Early or advanced stage (T1−2N0−1)
Totally laparoscopic or LAG: LAG
Inclusion criteria
1. Pathologically proven gastric adenocarcinoma
2. Age of 20 to 80 years
3. A preoperative stage of cT1N0M0, cT1N1m0, cT2aN0M0 according to
American Joint Committee on Cancer/Union for International Cancer Control 6th
edition
4. No history of other cancers
5. No history of chemotherapy or radiotherapy
Exclusion criteria
1. ASA class
3
2. Need for combined resection
3. Total gastrectomy
39Laparoscopic versus open gastrectomy for gastric cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kim 2015 (Continued)
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 644)
Further details: number of ports and incision size not stated
Group 2: open gastrectomy (n = 612)
Further details: Incision not stated
Nodes dissected and drain use: D1 or more nodal dissection; drain use not stated
Outcomes The outcomes reported were short-term mortality and complications
Notes Conversion to open gastrectomy: not reported
Follow-up period: 30 days
Reasons for post-randomisation drop-outs: Patients who switched to the other group’s
approach and underwent other than distal gastrectomy or combined resection except
cholecystectomy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After confirming the patients met the inclusion/
exclusion criteria by telephoning the data center, the pa-
tients were registered into the trial and then randomized
to one of two groups (LADG or ODG) on the basis of a
computer-generated randomization list”
Allocation concealment (selection bias) Low risk Quote: “Randomizationwas coordinated centrally by the
independent data center and aimed to balance the arms
according to each institution”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Comment: The severity of postoperative complications
was not reported
Other bias Low risk Comment: No other source of bias was identified
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Kitano 2002
Methods Randomised controlled trial
Participants Country: Japan
Number randomised: 28
Post-randomisation drop-outs: not stated
Number analysed: 28
Average age: 62 years
Females: 11 (39.3%)
Method of Anastamosis: Billroth-I; hand-sewn or stapler anastomosis not stated
Type of gastrectomy: Subtotal gastrectomy
Cancer stage: Early stage (T1N0)
Totally laparoscopic or LAG: LAG
Inclusion criteria
1. Patients undergoing distal gastrectomy for early gastric cancer
2. At risk of perigastric lymph node metastasis precluding endoscopic mucosal
resection
Exclusion criteria
1. Age over 80 years
2. Operative cardiovascular risk greater than that of New York Heart Association
class II
3. Operative pulmonary risk greater than that of Hugh-Jones class II
4. Severe liver disease (Child class B or C) or renal dysfunction
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 14)
Further details: number of ports not stated; upper midline incision (5 cm)
Group 2: open gastrectomy (n = 14)
Further details: Upper midline incision
Nodes dissected and drain use: Nodal dissection not stated; drain use not stated
Outcomes The outcomes reported were short-term mortality, complications, and long-term recur-
rence
Notes Conversion to open gastrectomy: 0/14 (0%)
Follow-up period: 26 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Low risk Quote: “After providing written informed consent, the
patients were randomly assigned to either LADG group
(n = 10) and an ODG group (n = 10) with Billroth-
I reconstruction on the day before operation by use of
numbered, sealed envelopes that were stratified by the
surgeon”
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Kitano 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: This information was not available
Selective reporting (reporting bias) High risk Comment: The severity of postoperative complications
was not reported
Other bias Low risk Comment: No other source of bias was identified
Lee 2005
Methods Randomised controlled trial
Participants Country: South Korea
Number randomised: 47
Post-randomisation drop-outs: not stated
Number analysed: 47
Average age: 58 years
Females: 21 (44.7%)
Method of Anastamosis: Billroth-I; stapler
Type of gastrectomy: Subtotal gastrectomy
Cancer stage: Early stage (T1N0)
Totally laparoscopic or LAG: LAG
Inclusion criteria
Patients with early gastric cancer undergoing distal gastrectomy
Exclusion criteria
1. Patients who had mucosal lesions that were suitable for an endoscopic mucosal
resection (lesion size < 20 mm in the elevated type and < 10 mm in the depressed type)
2. A surgical risk greater than ASA III
3. Lesions proximal to the midbody
4. A previous history of upper abdominal surgery
5. Need for combined surgery to treat another disease
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 24)
Further details: 4 ports; upper midline incision about 7 cm
Group 2: open gastrectomy (n = 23)
Further details: Upper midline incision (about 20 cm)
Nodes dissected and drain use: Selected nodes in laparoscopic group and D2 nodal
dissection in open group; drain used routinely in laparoscopic group; information on
drain use in open group was not available
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Lee 2005 (Continued)
Outcomes The outcomes reported were short-term mortality, complications, lymph nodes har-
vested, length of hospital stay, and long-term recurrence
Notes Conversion to open gastrectomy: 0/24 (0%)
Follow-up period: 14 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Using a random number table, 23 patients were
assigned to the open surgery group (group O) and 24
patients were assigned to the LADG group (group L)”
Allocation concealment (selection bias) Unclear risk Comment: This information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: This information was not available.
Selective reporting (reporting bias) High risk Comment: The severity of postoperative complications
was not reported
Other bias High risk Comment: Amore extensive procedure was performed in
open gastrectomy group compared to laparoscopic group.
This could potentially favour laparoscopic group in terms
of decreased complications but favour open group in
terms of decreased long-term recurrence and mortality
Sakuramoto 2013
Methods Randomised controlled trial
Participants Country: Japan
Number randomised: 64
Post-randomisation drop-outs: 1 (1.6%)
Number analysed: 63
Average age: 60 years
Females: 21 (33.3%)
Method of Anastamosis: Billroth-I; stapler
Type of gastrectomy: Subtotal gastrectomy
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Sakuramoto 2013 (Continued)
Cancer stage: Early stage (T1N0)
Totally laparoscopic or LAG: LAG
Inclusion criteria
Over 20 and under 75 years of age with gastric cancer in the middle or lower part of the
stomach for which distal gastrectomy was indicated
Exclusion criteria
1. Past history of gastric cancer
2. Previous open surgery of the upper abdomen
3. Past history of other types of cancers and cancer treatment
4. Serious heart, lung, kidney, blood and/or metabolic disease
5. New York Heart Association class III or IV classification of cardiac patients
6. Class III, IV, or V of the Hugh-Jones dyspnoea criteria
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 31)
Further details: 4 ports; upper abdominal incision about 5 cm
Group 2: open gastrectomy (n = 32)
Further details: Upper midline incision (xiphoid to umbilicus)
Nodes dissected and drain use: Selected group of nodes in the two groups; drains used
routinely in both groups
Outcomes The outcomes reported were short-termmortality, complications, and length of hospital
stay
Notes Conversion to open gastrectomy: not reported
Follow-up period: until discharge
Reasons for post-randomisation drop-outs: concurrent illness
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The computer-generated, nonstratified, blocked
randomization scheme was managed centrally and con-
cealed at the moment of inclusion”
Allocation concealment (selection bias) Low risk Quote: “The computer-generated, nonstratified, blocked
randomization scheme was managed centrally and con-
cealed at the moment of inclusion”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Due to the pragmatic nature of the trial, sur-
geons, care providers, and patients could not be blinded
to the type of treatment that was performed”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Due to the pragmatic nature of the trial, sur-
geons, care providers, and patients could not be blinded
to the type of treatment that was performed”
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Sakuramoto 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Comment: Postoperative mortality and morbidity were
reported
Other bias Low risk Comment: No other source of bias was identified
Takiguchi 2013
Methods Randomised controlled trial
Participants Country: Japan
Number randomised: 40
Post-randomisation drop-outs: not stated
Number analysed: 40
Average age: 62 years
Females: 15 (37.5%)
Method of Anastamosis: Billroth-I; stapler
Type of gastrectomy: Subtotal gastrectomy
Cancer stage: Early stage (T1N0−1)
Totally laparoscopic or LAG: LAG
Inclusion criteria
1. Age between 20 and 80 years
2. Performance status of ECOG (Eastern Cooperative Oncology Group) 0-1
3. Signed informed consent
4. Location of the primary tumour in the antrum, angle, and lower body
5. Histologically confirmed adenocarcinoma of the stomach with preoperative
staging of stage Ia or Ib (no evidence of distant metastasis or invasion of adjacent
organs or serosal infiltration by abdominal computed tomography [CT] and chest x-
ray film and regional lymph node metastasis confined to perigastric nodes [n1] as
shown on CT scan)
Exclusion criteria
1. Metastatic disease
2. Previous history of malignancy in any organ
3. Any comorbidity obviating major surgery
4. Contraindication to laparoscopy such as severe cardiac disease, abdominal wall
hernias, portal hypertension, pregnancy, previous upper abdominal major surgery
excluding appendectomy and laparoscopic cholecystectomy.
5. Complicated cases requiring emergency surgery
6. An accompanying surgical condition requiring surgery at the same time
Interventions Participants were randomly assigned to two groups
Group 1: laparoscopic gastrectomy (n = 20)
Further details: 5 ports; midline incision about 4 to 6 cm
Group 2: open gastrectomy (n = 20)
Further details: Incision not stated
Nodes dissected and drain use: Selected group of nodes in the two groups; drains used
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Takiguchi 2013 (Continued)
in laparoscopic group, no details in open group
Outcomes The outcomes reported were short-term mortality, blood transfusion, length of hospital
stay, lymph node harvest, and long-term mortality
Notes Conversion to open gastrectomy: 0/20 (0%)
Follow-up period: 60 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available
Allocation concealment (selection bias) Low risk Quote: “Randomization of the patients into two groups
was performed by the blind envelop method on the day
before operation, but the patients were not informed of
the results at that time”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: This was a single-blinded study in which only
patients were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: This was a single-blinded study in which only
patients were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: There were no post-randomisation drop-outs
Selective reporting (reporting bias) High risk Comment: The complications in the laparoscopic gas-
trectomy group and the severity of postoperative compli-
cations in the open gastrectomy group were not reported
Other bias Low risk Comment: No other source of bias was identified
ASA: American Society of Anesthesiologist; EMR: Endoscopic mucosal resection; FEV1: forced expiratory volume in first second;
JCOG: Japan Clinical Oncology Group; LADG: laparoscopy-assisted distal gastrectomy; LAG: laparoscopy-assisted gastrectomy;
ODG: open distal gastrectomy
T: Tumour stage of TNM classification
N: Nodal stage of TNM classification
Example: T1−2N0−1: indicates T-stage 1 or 2 and N-stage 0 or 1
Early gastric cancer: clinical stage: T1Nany
Advaced gastric cancer: T>1Nany
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Han 2014 Not a randomised controlled trial
Kanellos 2009 Editorial
Kawamura 2008 Not a randomised controlled trial
Kim 2008 Quasi-randomised study
Kim 2009 Comment on an excluded study (Kim 2008)
Lee 2008 Not a randomised controlled trial
Lee 2009 Not a randomised controlled trial
Li 2014 Not a randomised controlled trial
Liakakos 2009 Comment on an excluded study (Kim 2008)
Lin 2014 Not a randomised controlled trial
Sakuramoto 2009 Not a randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Haverkamp 2015
Trial name or title LOGICA
Methods Randomised controlled trial
Participants Early or advanced staged gastric adenocarcinoma
Interventions Laparosopy-assisted versus open distal or total gastrectomy
Outcomes Mortality, adverse events, health-related quality of life, length of hospital stay, clear resection margins, number
of lymph nodes dissected, and long-term mortality
Starting date December 2014
Contact information R.vanHillegersberg@umcutrecht.nl
Notes
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Straatman 2015
Trial name or title STOMACH
Methods Randomised controlled trial
Participants People with early or advanced gastric cancer receiving neoadjuvant chemotherapy
Interventions Laparosopy-assisted versus open total gastrectomy
Outcomes Mortality, health-related quality of life, length of hospital stay, number of lymph nodes dissected, and long-
term mortality
Starting date Not stated
Contact information je.straatman@vumc.nl
Notes
Yoshikawa 2012
Trial name or title LANDSCOPE
Methods Randomised controlled trial
Participants People with advanced gastric cancer receiving neoadjuvant chemotherapy
Interventions Laparosopy-assisted versus open distal gastrectomy
Outcomes Mortality, adverse events, and long-term recurrence
Starting date December 2014
Contact information yoshikawat@kcch.jp
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Laparoscopic versus open gastrectomy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term mortality 11 2335 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [0.50, 5.10]
2 Long-term mortality (maximal
follow-up)
3 195 Hazard Ratio (Fixed, 95% CI) 0.94 [0.70, 1.25]
3 Proportion with a serious adverse
event (< 3 months)
8 432 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.27, 1.34]
4 Short-term recurrence 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Long-term recurrence (maximal
follow-up)
4 Hazard Ratio (Fixed, 95% CI) Totals not selected
6 Proportion with an adverse event
(< 3 months)
11 2490 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.60, 1.01]
7 Proportion requiring blood
transfusion during or within a
week of surgery
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Quantity of perioperative blood
transfused
2 143 Std. Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.27, 0.38]
9 Length of hospital stay 8 444 Mean Difference (IV, Random, 95% CI) -1.38 [-2.57, -0.19]
10 Proportion with positive
resection margins at
histopathological examination
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
11 Number of lymph nodes
harvested
9 472 Mean Difference (IV, Fixed, 95% CI) -0.63 [-1.51, 0.25]
Comparison 2. Laparoscopic versus open gastrectomy (subgroup analysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term mortality (stratified
by early versus advanced
cancer)
7 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Early gastric cancer 5 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Advanced gastric cancer 2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Long-term mortality (maximal
follow-up) (stratified by early
versus advanced cancer)
2 Hazard Ratio (Fixed, 95% CI) Totals not selected
2.1 Early gastric cancer 1 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Advanced gastric cancer 1 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
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3 Proportion with a serious adverse
event (< 3 months) (stratified
by early versus advanced
cancer)
5 262 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.21, 1.60]
3.1 Early gastric cancer 4 166 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.14, 1.39]
3.2 Advanced gastric cancer 1 96 Risk Ratio (M-H, Fixed, 95% CI) 2.88 [0.12, 68.98]
4 Short-term mortality (stratified
by type of gastrectomy)
10 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Subtotal gastrectomy 10 2239 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [0.50, 5.10]
5 Long-term mortality (maximal
follow-up) (stratified by type of
gastrectomy)
2 Hazard Ratio (Fixed, 95% CI) Totals not selected
5.1 Subtotal gastrectomy 2 Hazard Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Proportion with a serious adverse
event (< 3 months) (stratified
by type of gastrectomy)
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Subtotal gastrectomy 7 336 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.22, 1.22]
Analysis 1.1. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 1 Short-term mortality.
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 1 Short-term mortality
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aoyama 2014 0/13 0/13 Not estimable
Cai 2011 0/49 0/47 Not estimable
Chen Hu 2012 0/41 0/44 Not estimable
Hayashi 2005 0/14 0/14 Not estimable
Hu 2015 2/308 0/299 11.0 % 4.85 [ 0.23, 100.69 ]
Huscher 2005 1/30 2/29 44.3 % 0.48 [ 0.05, 5.05 ]
Kim 2015 4/644 2/612 44.7 % 1.90 [ 0.35, 10.34 ]
Kitano 2002 0/14 0/14 Not estimable
Lee 2005 0/24 0/23 Not estimable
Sakuramoto 2013 0/31 0/32 Not estimable
Takiguchi 2013 0/20 0/20 Not estimable
Total (95% CI) 1188 1147 100.0 % 1.60 [ 0.50, 5.10 ]
0.01 0.1 1 10 100
Favours laparoscopic Favours open
(Continued . . . )
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(. . . Continued)
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 7 (Laparoscopic gastrectomy), 4 (Open gastrectomy)
Heterogeneity: Chi2 = 1.55, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laparoscopic Favours open
Analysis 1.2. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 2 Long-term mortality
(maximal follow-up).
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 2 Long-term mortality (maximal follow-up)
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Cai 2011 49 47 -0.04 (0.35) 17.3 % 0.96 [ 0.48, 1.91 ]
Huscher 2005 30 29 -0.07 (0.16) 82.7 % 0.93 [ 0.68, 1.28 ]
Takiguchi 2013 20 20 0 (0) Not estimable
Total (95% CI) 99 96 100.0 % 0.94 [ 0.70, 1.25 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours laparoscopic Favours open
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Analysis 1.3. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 3 Proportion with a serious
adverse event (< 3 months).
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 3 Proportion with a serious adverse event (< 3 months)
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aoyama 2014 0/13 1/13 10.0 % 0.33 [ 0.01, 7.50 ]
Cai 2011 1/49 0/47 3.4 % 2.88 [ 0.12, 68.98 ]
Chen Hu 2012 2/41 1/44 6.4 % 2.15 [ 0.20, 22.79 ]
Hayashi 2005 1/14 3/14 20.0 % 0.33 [ 0.04, 2.83 ]
Huscher 2005 1/30 3/29 20.3 % 0.32 [ 0.04, 2.92 ]
Kitano 2002 1/14 0/14 3.3 % 3.00 [ 0.13, 67.91 ]
Lee 2005 0/24 2/23 17.0 % 0.19 [ 0.01, 3.80 ]
Sakuramoto 2013 1/31 3/32 19.6 % 0.34 [ 0.04, 3.13 ]
Total (95% CI) 216 216 100.0 % 0.60 [ 0.27, 1.34 ]
Total events: 7 (Laparoscopic gastrectomy), 13 (Open gastrectomy)
Heterogeneity: Chi2 = 4.61, df = 7 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laparoscopic Favours open
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Analysis 1.4. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 4 Short-term recurrence.
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 4 Short-term recurrence
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hayashi 2005 0/14 0/14 Not estimable
Kitano 2002 0/14 0/14 Not estimable
Lee 2005 0/24 0/23 Not estimable
0.01 0.1 1 10 100
Favours laparoscopic Favours open
Analysis 1.5. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 5 Long-term recurrence
(maximal follow-up).
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 5 Long-term recurrence (maximal follow-up)
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Hayashi 2005 14 14 0 (0) Not estimable
Huscher 2005 30 29 -0.05 (0.16) 0.95 [ 0.70, 1.30 ]
Kitano 2002 14 14 0 (0) Not estimable
Lee 2005 24 23 0 (0) Not estimable
0.5 0.7 1 1.5 2
Favours laparoscopic Favours open
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Analysis 1.6. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 6 Proportion with an adverse
event (< 3 months).
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 6 Proportion with an adverse event (< 3 months)
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aoyama 2014 1/13 1/13 0.9 % 1.00 [ 0.07, 14.34 ]
Cai 2011 6/49 9/47 6.0 % 0.64 [ 0.25, 1.66 ]
Chen Hu 2012 20/41 22/44 16.5 % 0.98 [ 0.63, 1.50 ]
Hayashi 2005 4/14 8/14 6.1 % 0.50 [ 0.19, 1.29 ]
Hu 2015 58/308 44/299 19.1 % 1.28 [ 0.89, 1.83 ]
Huscher 2005 8/30 10/29 8.2 % 0.77 [ 0.36, 1.68 ]
Kim 2013 17/100 18/95 11.5 % 0.90 [ 0.49, 1.64 ]
Kim 2015 84/644 122/612 23.3 % 0.65 [ 0.51, 0.84 ]
Kitano 2002 2/14 4/14 2.6 % 0.50 [ 0.11, 2.30 ]
Lee 2005 3/24 10/23 4.3 % 0.29 [ 0.09, 0.91 ]
Sakuramoto 2013 1/31 5/32 1.5 % 0.21 [ 0.03, 1.67 ]
Total (95% CI) 1268 1222 100.0 % 0.78 [ 0.60, 1.01 ]
Total events: 204 (Laparoscopic gastrectomy), 253 (Open gastrectomy)
Heterogeneity: Tau2 = 0.06; Chi2 = 16.19, df = 10 (P = 0.09); I2 =38%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laparoscopic Favours open
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Analysis 1.7. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 7 Proportion requiring blood
transfusion during or within a week of surgery.
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 7 Proportion requiring blood transfusion during or within a week of surgery
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aoyama 2014 0/13 0/13 Not estimable
Takiguchi 2013 0/20 0/20 Not estimable
0.005 0.1 1 10 200
Favours laparoscopic Favours open
Analysis 1.8. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 8 Quantity of perioperative
blood transfused.
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 8 Quantity of perioperative blood transfused
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cai 2011 49 0.09 (0.169) 47 0.08 (0.147) 67.1 % 0.09 [ -0.31, 0.49 ]
Lee 2005 24 0.08 (0.4) 23 0.09 (0.3) 32.9 % -0.03 [ -0.60, 0.54 ]
Total (95% CI) 73 70 100.0 % 0.05 [ -0.27, 0.38 ]
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 9 Length of hospital stay.
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 9 Length of hospital stay
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Random,95% CI IV,Random,95% CI
Cai 2011 49 11.6 (2.9) 47 11.4 (1.2) 20.1 % 0.20 [ -0.68, 1.08 ]
Chen Hu 2012 41 7.3 (4.2) 44 8.1 (15.5) 4.9 % -0.80 [ -5.56, 3.96 ]
Hayashi 2005 14 12 (2) 12 18 (6) 7.5 % -6.00 [ -9.55, -2.45 ]
Huscher 2005 30 10.3 (3.6) 29 14.5 (4.6) 13.2 % -4.20 [ -6.31, -2.09 ]
Kitano 2002 14 17.6 (2.6) 14 16 (4) 11.3 % 1.60 [ -0.90, 4.10 ]
Lee 2005 24 11.2 (4.2) 23 17.3 (15.5) 2.9 % -6.10 [ -12.65, 0.45 ]
Sakuramoto 2013 31 9.1 (1.1) 32 10 (3.1) 18.7 % -0.90 [ -2.04, 0.24 ]
Takiguchi 2013 20 10 (0.9) 20 11 (0.9) 21.5 % -1.00 [ -1.56, -0.44 ]
Total (95% CI) 223 221 100.0 % -1.38 [ -2.57, -0.19 ]
Heterogeneity: Tau2 = 1.63; Chi2 = 29.62, df = 7 (P = 0.00011); I2 =76%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 10 Proportion with positive
resection margins at histopathological examination.
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 10 Proportion with positive resection margins at histopathological examination
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kitano 2002 0/14 0/14 Not estimable
0.01 0.1 1 10 100
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Analysis 1.11. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 11 Number of lymph nodes
harvested.
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 1 Laparoscopic versus open gastrectomy
Outcome: 11 Number of lymph nodes harvested
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Aoyama 2014 13 40.5 (81.1) 13 43 (81.1) 0.0 % -2.50 [ -64.85, 59.85 ]
Cai 2011 49 23 (2.7) 47 22.9 (2.4) 74.1 % 0.10 [ -0.92, 1.12 ]
Chen Hu 2012 41 18.3 (6.3) 44 19 (6.3) 10.7 % -0.70 [ -3.38, 1.98 ]
Hayashi 2005 14 28 (14) 14 27 (10) 1.0 % 1.00 [ -8.01, 10.01 ]
Huscher 2005 30 30 (81.6) 29 33.4 (93.7) 0.0 % -3.40 [ -48.30, 41.50 ]
Kitano 2002 14 20.2 (3.6) 14 24.9 (3.5) 11.2 % -4.70 [ -7.33, -2.07 ]
Lee 2005 24 31.8 (13.5) 23 38.1 (15.9) 1.1 % -6.30 [ -14.75, 2.15 ]
Sakuramoto 2013 31 31.6 (12.2) 32 33.8 (13.4) 1.9 % -2.20 [ -8.52, 4.12 ]
Takiguchi 2013 20 33 (81.6) 20 32 (93.7) 0.0 % 1.00 [ -53.45, 55.45 ]
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(Continued . . . )
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(. . . Continued)
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 236 236 100.0 % -0.63 [ -1.51, 0.25 ]
Heterogeneity: Chi2 = 13.28, df = 8 (P = 0.10); I2 =40%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 1 Short-
term mortality (stratified by early versus advanced cancer).
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)
Outcome: 1 Short-term mortality (stratified by early versus advanced cancer)
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Early gastric cancer
Hayashi 2005 0/14 0/14 Not estimable
Kitano 2002 0/14 0/14 Not estimable
Lee 2005 0/24 0/23 Not estimable
Sakuramoto 2013 0/31 0/32 Not estimable
Takiguchi 2013 0/20 0/20 Not estimable
2 Advanced gastric cancer
Cai 2011 0/49 0/47 Not estimable
Hu 2015 2/308 0/299 4.85 [ 0.23, 100.69 ]
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Analysis 2.2. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 2 Long-
term mortality (maximal follow-up) (stratified by early versus advanced cancer).
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)
Outcome: 2 Long-term mortality (maximal follow-up) (stratified by early versus advanced cancer)
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Early gastric cancer
Takiguchi 2013 0 (0) Not estimable
2 Advanced gastric cancer
Cai 2011 -0.04 (0.35) 0.96 [ 0.48, 1.91 ]
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Analysis 2.3. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 3
Proportion with a serious adverse event (< 3 months) (stratified by early versus advanced cancer).
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)
Outcome: 3 Proportion with a serious adverse event (< 3 months) (stratified by early versus advanced cancer)
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Early gastric cancer
Hayashi 2005 1/14 3/14 31.5 % 0.33 [ 0.04, 2.83 ]
Kitano 2002 1/14 0/14 5.3 % 3.00 [ 0.13, 67.91 ]
Lee 2005 0/24 2/23 26.8 % 0.19 [ 0.01, 3.80 ]
Sakuramoto 2013 1/31 3/32 31.0 % 0.34 [ 0.04, 3.13 ]
Subtotal (95% CI) 83 83 94.6 % 0.44 [ 0.14, 1.39 ]
Total events: 3 (Laparoscopic gastrectomy), 8 (Open gastrectomy)
Heterogeneity: Chi2 = 1.86, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
2 Advanced gastric cancer
Cai 2011 1/49 0/47 5.4 % 2.88 [ 0.12, 68.98 ]
Subtotal (95% CI) 49 47 5.4 % 2.88 [ 0.12, 68.98 ]
Total events: 1 (Laparoscopic gastrectomy), 0 (Open gastrectomy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Total (95% CI) 132 130 100.0 % 0.58 [ 0.21, 1.60 ]
Total events: 4 (Laparoscopic gastrectomy), 8 (Open gastrectomy)
Heterogeneity: Chi2 = 3.04, df = 4 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 1.18, df = 1 (P = 0.28), I2 =15%
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Analysis 2.4. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 4 Short-
term mortality (stratified by type of gastrectomy).
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)
Outcome: 4 Short-term mortality (stratified by type of gastrectomy)
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Subtotal gastrectomy
Aoyama 2014 0/13 0/13 Not estimable
Chen Hu 2012 0/41 0/44 Not estimable
Hayashi 2005 0/14 0/14 Not estimable
Hu 2015 2/308 0/299 11.0 % 4.85 [ 0.23, 100.69 ]
Huscher 2005 1/30 2/29 44.3 % 0.48 [ 0.05, 5.05 ]
Kim 2015 4/644 2/612 44.7 % 1.90 [ 0.35, 10.34 ]
Kitano 2002 0/14 0/14 Not estimable
Lee 2005 0/24 0/23 Not estimable
Sakuramoto 2013 0/31 0/32 Not estimable
Takiguchi 2013 0/20 0/20 Not estimable
Subtotal (95% CI) 1139 1100 100.0 % 1.60 [ 0.50, 5.10 ]
Total events: 7 (Laparoscopic gastrectomy), 4 (Open gastrectomy)
Heterogeneity: Chi2 = 1.55, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 5 Long-
term mortality (maximal follow-up) (stratified by type of gastrectomy).
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)
Outcome: 5 Long-term mortality (maximal follow-up) (stratified by type of gastrectomy)
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Subtotal gastrectomy
Huscher 2005 -0.07 (0.16) 0.93 [ 0.68, 1.28 ]
Takiguchi 2013 0 (0) Not estimable
0.5 0.7 1 1.5 2
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Analysis 2.6. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 6
Proportion with a serious adverse event (< 3 months) (stratified by type of gastrectomy).
Review: Laparoscopic versus open gastrectomy for gastric cancer
Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)
Outcome: 6 Proportion with a serious adverse event (< 3 months) (stratified by type of gastrectomy)
Study or subgroup
Laparoscopic
gastrectomy Open gastrectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Subtotal gastrectomy
Aoyama 2014 0/13 1/13 10.3 % 0.33 [ 0.01, 7.50 ]
Chen Hu 2012 2/41 1/44 6.6 % 2.15 [ 0.20, 22.79 ]
Hayashi 2005 1/14 3/14 20.7 % 0.33 [ 0.04, 2.83 ]
Huscher 2005 1/30 3/29 21.0 % 0.32 [ 0.04, 2.92 ]
Kitano 2002 1/14 0/14 3.4 % 3.00 [ 0.13, 67.91 ]
Lee 2005 0/24 2/23 17.6 % 0.19 [ 0.01, 3.80 ]
Sakuramoto 2013 1/31 3/32 20.3 % 0.34 [ 0.04, 3.13 ]
Subtotal (95% CI) 167 169 100.0 % 0.52 [ 0.22, 1.22 ]
Total events: 6 (Laparoscopic gastrectomy), 13 (Open gastrectomy)
Heterogeneity: Chi2 = 3.58, df = 6 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 (carcin* or cancer* or neoplas* or tumour* or tumor* or cyst* or growth* or adenocarcin* or malig*)
#2 (Intestin* or Digest* or Gastr* or gut or epigastr* or stomach* or abdomin*)
#3 #1 or #2
#4 MeSH descriptor: [Abdominal Neoplasms] explode all trees
#5 MeSH descriptor: [Intestinal Neoplasms] explode all trees
#6 MeSH descriptor: [Stomach Neoplasms] explode all trees
#7 #4 or #5 or #6
#8 #3 or #7
#9 (laparoscopy or laparoscopic)
#10 MeSH descriptor: [Laparoscopy] explode all trees
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#11 #9 or #10
#12 gastrectomy
#13 MeSH descriptor: [Gastrectomy] explode all trees
#14 #12 or #13
#15 #8 and #11 and #14
Appendix 2. MEDLINE search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. (carcin* or cancer* or neoplas* or tumour* or tumor* or cyst* or growth* or adenocarcin* or malig*).mp.
13. (Intestin* or Digest* or Gastr* or gut or epigastr* or stomach*).mp.
14. 12 and 13
15. exp abdominal neoplasms/ or exp intestinal neoplasms/ or exp stomach neoplasms/
16. 14 or 15
17. (laparoscopy or laparoscopic).mp.
18. exp Laparoscopy/
19. 17 or 18
20. exp Gastrectomy/
21. gastrectomy.mp.
22. 20 or 21
23. 16 and 19 and 22
24. 11 and 23
Appendix 3. EMBASE search strategy
1. Clinical trial/
2. Randomized controlled trial/
3. Randomization/
4. Single-Blind Method/
5. Double-Blind Method/
6. Cross-Over Studies/
7. Random Allocation/
8. Placebo/
9. Randomi?ed controlled trial*.tw.
10. Rct.tw.
11. Random allocation.tw.
12. Randomly allocated.tw.
13. Allocated randomly.tw.
14. (allocated adj2 random).tw.
15. Single blind*.tw.
16. Double blind*.tw.
17. ((treble or triple) adj blind*).tw.
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18. Placebo*.tw.
19. Prospective study/
20. or/1-19
21. Case study/
22. Case report.tw.
23. Abstract report/ or letter/
24. or/21-23
25. 20 not 24
26. (carcin* or cancer* or neoplas* or tumour* or tumor* or cyst* or growth* or adenocarcin* or malig*).mp.
27. exp neoplasm/ or exp tumor/
28. 26 or 27
29. (Intestin* or Digest* or Gastr* or gut or epigastr* or stomach*).mp.
30. 28 and 29
31. exp stomach tumor/ or exp abdominal tumor/ or exp stomach cancer/ or exp abdominal cancer/ or exp intestine cancer/ or exp
stomach carcinoma/ or exp stomach carcinogenesis/ or exp stomach carcinoid/
32. 30 or 31
33. (laparoscopy or laparoscopic).mp.
34. exp laparoscopy/
35. 33 or 34
36. exp gastrectomy Billroth I/ or exp gastrectomy/ or exp partial gastrectomy/ or exp gastrectomy Billroth II/
37. gastrectomy.mp.
38. 36 or 37
39. 32 and 35 and 38
40. 25 and 39
Appendix 4. Science Citation Index search strategy
#1 TS=(carcin* or cancer* or neoplas* or tumour* or tumor* or cyst* or growth* or adenocarcin* or malig*)
#2 TS=(Intestin* or Digest* or Gastr* or gut or epigastr* or stomach*)
#3 TS=(laparoscopy or laparoscopic)
#4 TS=(gastrectomy)
#5 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-analysis OR systematic review* OR meta-
analys*)
#6 #5 AND #4 AND #3 AND #2 AND #1
Appendix 5. ClinicalTrials.gov search strategy
“Interventional” [STUDY-TYPES] AND gastrectomy [DISEASE] AND (laparoscopy OR laparoscopic) [TREATMENT] AND (
“Phase 2” OR “Phase 3” OR “Phase 4” ) [PHASE]
Appendix 6. WHO ICTRP search strategy
Gastrectomy AND laparoscop*
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